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Although	  complex	   inflammatory	  diseases	  affect	  5%	  of	   the	  population	  we	  still	  do	  
not	  understand	  fully	  the	  underlying	  disease	  triggers	  and	  mechanisms.	  This	  partly	  
explains	  why	  current	  treatments	  are	  not	  curative	  but	  only	  modify	  disease.	  	  These	  
diseases	  arise	  from	  combined	  genetic,	  environmental	  and	  unknown	  effects.	  	  
In	   this	   thesis,	   I	   have	   focused	   on	   identifying	   the	   genetic	   factors	   that	   regulate	  
complex	   disease	   in	   experimental	   models.	   The	   rationale	   is	   that	   these	   genetic	  
determinants	  will	  provide	   insight	   into	  the	  conserved	  mechanisms	  also	   important	  
for	   human	   disease.	   These	   mechanisms	   can	   then	   be	   targeted	   therapeutically.	   I	  
have	   worked	   with	   the	   neuroinflammatory	   diseases	   multiple	   sclerosis	   (MS)	   and	  
Guillain-­‐Barré	  syndrome	  (GBS)	  and	   their	   respective	  animal	  models,	  experimental	  
autoimmune	   encephalomyelitis	   (EAE)	   and	   experimental	   autoimmune	   neuritis	  
(EAN).	  	  
To	   identify	   risk	   genes	   in	   an	   unbiased	   phenotype-­‐driven	  manner,	  we	   established	  
intercrosses	   and	   recombinant	   lines	   between	   rat	   strains	   with	   opposing	  
susceptibilities	   to	   EAE	   and	   EAN.	   Linkage	   analyses	   and	   functional	   studies	   in	   rat	  
lines	   then	   successfully	   positioned	   five	   genes	   that	   regulate	   experimental	  
neuroinflammation,	  namely	   Il22ra2,	  Vav1,	  Raet1,	  Klrk1	   and	  Ncf1.	   IL22RA2	   and	  VAV1	  
were	  also	  translated	  as	  risk	  genes	  in	  MS	  cohorts.	  	  
More	   importantly,	   however,	   the	   five	   genes	   targeted	   immune	   mechanisms	   and	  
events	   that	   correlated	   well	   with	   disease.	   In	   our	   hands,	   Il22ra2	   regulated	  
macrophage	   activation,	   Vav1	   controlled	   effector	   T	   cell	   activity	   and	   regulatory	   T	  
cell	  proportions,	  Raet1	  and	  Klrk1	  displayed	  a	  gene-­‐gene	  interaction	  that	  modified	  
NK	   cell	   activity	   and	   Ncf1	   controlled	  oxidative	   burst	   from	  mononuclear	   cells.	   All	  
these	  mechanisms	  also	  have	  described	  roles	  in	  both	  MS	  and	  GBS.	  
By	  finding	  genetic	  determinants	  of	  distinct	  pathogenic	  mechanisms	  we	  may	  both	  
discover	   novel	   targets	   for	   treatment	   and	   also	   more	   accurately	   define	   which	  
current	  therapies	  are	  more	  suitable	  for	  different	  patients.	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1.	  GENETIC	  BACKGROUND	  
	  
Most,	   if	   not	   all,	   diseases	   have	   a	   hereditary	   component.	   This	   has	   primarily	   been	  
established	   in	   family	   studies,	   in	   which	   an	   increased	   disease	   risk	   is	   observed	   in	  
relatives	  of	  affected	  individuals.	  For	  monogenic	  diseases	  this	  familial	  aggregation	  
is	   caused	   by	   mutations	   in	   a	   single	   gene.	   Most	   genes	   underlying	   monogenic	  
diseases	   have	   been	   identified	   as	   a	   result	   of	   human	   genetic	   studies	   (1).	   This	  
includes	  diseases	  such	  as	  cystic	  fibrosis,	  caused	  by	  mutations	  in	  the	  cystic	  fibrosis	  
transmembrane	   conductance	   regulator	   (CFTR)	   gene,	   and	   Huntington’s	   disease,	  
driven	   by	   mutations	   in	   the	   huntingtin	   gene.	   Although	   monogenic	   diseases	   can	  
often	  be	   severe	   they	  are	   typically	   rare	   in	   the	  general	  population	  and	   the	  global	  
prevalence	  of	  all	  known	  single-­‐gene	  diseases	  is	  approximately	  1%	  (2).	  	  
	  
The	   majority	   of	   diseases	   are	   polygenic	   in	   nature,	   meaning	   that	   multiple	   genes	  
regulate	  disease.	  These	  genes,	  or	  alleles,	  will	  often	  exert	  a	  small	  effect	  to	  increase	  
the	  overall	  disease	  susceptibility.	  The	  combined	  effect	  of	  these	  genes	  on	  disease	  
can	  be	  additive,	  meaning	  that	  each	  gene’s	  effect	  is	  independent	  of	  the	  other,	  or	  it	  
can	  be	  multiplicative	  as	  a	  result	  of	  gene-­‐gene	  interactions	  (3).	  
	  
Polygenic	   diseases	   also	   arise	   from	   environmental	   and	   as	   yet	   undefined	   factors,	  
often	  interacting	  with	  genetic	  factors.	  Most	  polygenic	  diseases	  are	  therefore	  also	  
referred	   to	   as	   complex	   diseases.	   Examples	   of	   complex	  diseases	   are	  most	   of	   the	  
disorders	   we	   see	   around	   us,	   ranging	   from	   depression,	   anxiety	   and	   metabolic	  
disorders	   to	   chronic	   inflammatory	   conditions	   such	   as	   Crohn’s	   disease	   (CD),	  
rheumatoid	  arthritis	   (RA),	   type	   1	  diabetes	   (T1D)	  and	  multiple	  sclerosis	   (MS).	  The	  
environmental	  factors	  are	  difficult	  to	  assess	  properly	  and	  can	  strongly	  confound	  
human	   genetic	   studies	   (4).	   The	   complexity	   of	   the	   interplay	   between	   subtle	  
genetic	   and	   environmental	   risk	   factors	   likely	   explains	   why	   a	   given	   risk	   allele	  
combination	  will	  not	  always	  produce	  the	  same	  phenotype	  (disease	  symptoms)	  in	  
every	   individual.	   This	  variation	   so	  often	  observed	   in	   complex	  diseases	   is	   termed	  
phenotypic	  heterogeneity.	  In	  addition,	  different	  gene	  combinations	  can	  cause	  the	  
same	  disease	  phenotype	  and	  this	  is	  termed	  genetic	  heterogeneity.	  The	  combined	  
risk	  from	  genetic	  and	  environmental	  factors	  will	  shift	  an	  individual’s	  risk	  towards	  




	  	   2	  
	  
Disease	   etiology	   is	   often	   poorly	   understood	   for	   complex	   disorders.	   By	   studying	  
their	  genetic	  basis	  we	  have	  a	  better	  chance	  to	  understand	  the	  events	  that	  drive	  
disease	  in	  some	  individuals	  but	  not	  in	  others.	  
	  
	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure 1. A schematic threshold model for genetic susceptibility to complex diseases. The 
combination of risk alleles (represented by filled blocks), either alone or in interaction, 
determines the overall risk of developing disease. The effect of one gene can vary from 
individual to individual, depending on interactions with other genes/environment, as 
demonstrated by the bars of different sizes with the same color. This susceptibility is further 
affected by environmental and stochastic factors.  
	  
This	  thesis	  explores	  the	  genetic	  regulation	  of	  complex	  inflammatory	  disorders,	  by	  
identifying	  risk	  genes	  and	  defining	  their	  roles	  in	  disease	  pathogenesis.	  I	  focus	  on	  
the	  neuroinflammatory	  diseases	  MS	  and	  Guillain-­‐Barré	  syndrome	  (GBS)	  and	  their	  
respective	  animal	  models.	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2.	  MS	  AND	  NEUROINFLAMMATION	  
	  
MS	   is	   a	   chronic	   inflammatory	   disease	   of	   the	   central	   nervous	   system	   (CNS).	   It	  
affects	  over	  2	  million	  people	  worldwide	  with	  a	  prevalence	  in	  Sweden	  of	  0.1	  -­‐	  0.2%	  
(7).	  Like	  most	  autoimmune	  disorders,	   it	   is	  more	  common	  in	  women	  than	   in	  men	  
with	  an	  approximate	  ratio	  of	  2.5:1	  (8,	  9).	  MS	  results	  from	  an	  attack	  of	  the	  immune	  
system	  on	  the	  oligodendrocytes,	  which	  produce	  the	  myelin	  sheaths	  that	  surround	  
the	   axons	   in	   the	   CNS.	   As	   the	   disease	   progresses,	   or	   possibly	   in	   parallel	   to	   the	  
demyelination,	  there	  is	  also	  axonal	  damage	  (10).	  The	  symptoms	  of	  MS	  vary	  widely	  
depending	  on	  which	   signals	   are	   interrupted.	   They	   include	   changes	   in	   sensation,	  
visual	   problems,	   muscle	   weakness,	   coordination	   and	   speech	   difficulties,	   severe	  
fatigue,	   cognitive	   impairment,	   balance	   disturbance	   and	   pain.	   In	   more	   severe	  
cases,	  MS	  causes	  impaired	  mobility	  and	  disability.	  
MS	   can	   exhibit	   several	   different	   forms	   of	   progression	   with	   symptoms	   either	  
occurring	   in	   discrete	   attacks	   or	   slowly	   becoming	  more	   severe	   over	   time.	   These	  
symptoms	   sometimes	   resolve	   completely	   between	   attacks	   but	   permanent	  
neurological	  problems	  often	  persist,	  especially	  as	  the	  disease	  advances	  (Figure	  2).	  	  
	  
	  	  
Figure 2. Different disease courses of MS. A) Progressive-relapsing MS; steady decline with 
superimposed attacks. B) Secondary-progressive MS; initially relapse-remitting MS, but then 
begins to decline without remission. C) Primary progressive MS; steady decline without 
remission. D) Relapse-remitting MS; unpredictable bouts which sometimes cause permanent 
damage, followed by periods of remission. 
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Relapsing-­‐remitting	  MS	   is	   the	  most	   common	   form,	   affecting	   85%	   of	   patients.	   A	  
majority	   of	   these	   patients	   eventually	   progress	   to	   the	   secondary-­‐progressive	  
phase.	  Onset	  of	  MS	  occurs	  between	  the	  ages	  20-­‐40	  years	  and	  50%	  of	  MS	  patients	  
are	   unable	   to	   work	   10	   years	   after	   diagnosis	   and	   are	   thus	   excluded	   from	   the	  
workforce.	  The	  magnitude	  of	  the	  socio-­‐economical	  impact	  is	  reflected	  in	  that	  MS,	  
constitutes	   the	   same	   overall	   economic	   burden	   on	   society	   as	   RA,	   which	   is	   five	  
times	  more	  prevalent	  than	  MS	  (Kristina	  Gottberg,	  personal	  communication).	  	  	  
2.1.	  HISTOPATHOLOGY	  OF	  MS	  
The	   main	   histopathological	   hallmark	   of	   MS	   is	   focal	   demyelinated	   lesions.	   The	  
detection	   of	   different	   patterns	   of	   demyelination	   suggests	   heterogeneity	   in	   the	  
mechanisms	   involved	   in	   lesion	   development.	   Different	   types	   of	   lesions,	   or	  
plaques,	   can	   be	   present	   in	   the	   same	   patient	   at	   various	   stages	   (11).	   The	   most	  
common	   pattern	   is	   characterized	   by	   perivascular	   inflammation,	   infiltrating	   T	  
lymphocytes,	  macrophages	  with	   increased	  complement	  at	   sites	  of	  active	  myelin	  
breakdown.	  In	  addition,	  deposition	  of	  immunoglobulin	  Gs	  (IgGs)	  can	  be	  detected	  
around	   lesions.	  Alternatively,	   lesions	   can	  display	  patterns	  of	   prominent	   signs	  of	  
oligodendrocyte	  dystrophy	  without	  IgG	  or	  complement	  deposition,	  suggestive	  of	  
primary	  oligodendrocyte	  damage	  (11).	  
	  
2.2.	  GENETICS	  OF	  MS	  
The	   genetic	   component	   in	   MS	   is	   well	   established.	   There	   is	   a	   clear	   increase	   in	  
recurrence	   risk	   in	   families	   of	   affected	   individuals	   compared	   to	   the	   general	  
population	  (12,	  13),	  whereas	  adoptee	  studies	  reveal	  no	   increased	  risk	  for	  disease	  
compared	  to	  the	  general	  population	  (14).	  Twin	  studies	  have	  consistently	  proven	  
that	   MS	   concordance	   is	   increased	   among	   monozygotic	   twins	   compared	   to	  
dizygotic	  twins	  (15-­‐17).	  As	  one	  moves	  from	  siblings	  to	  more	  distant	  relatives,	  the	  
risk	  decreases	  while	  still	  being	  higher	  than	  the	  general	  population	  (18).	  
The	  relevance	  of	  the	  major	  histocompatibility	  complex	  (MHC)	  locus,	  referred	  to	  as	  
the	   human	   leukocyte	   antigen	   (HLA)	   complex	   in	   humans,	   in	   MS	   has	   been	   well	  
documented.	   It	   unambiguously	   associates	   with	   disease	   in	   virtually	   all	   genetic	  
studies	   (19-­‐23).	   During	   the	   past	   years	   the	   effects	   within	   the	   HLA	   have	   been	  
refined,	   with	   Class	   II	   HLA-­‐DRB1*1501	   alleles	   being	   the	   major	   single	   genetic	   risk	  
factor	   (24,	   25).	   Conversely,	   HLA-­‐A2*0201	   alleles	   confer	   the	   strongest	   protective	  
influence	   (26).	   Moreover,	   it	   is	   clear	   that	   interactions	   between	   HLA	   haplotypes	  
exert	   even	   stronger	   effects	   (27-­‐29).	   More	   recent	   large	   studies	   have	   now	   also	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identified	  non-­‐MHC	  risk	  genes,	  such	  as	  interleukin	  7	  receptor	  (IL7R),	  IL2RA,	  CD58,	  
CLEC16A,	   KIF5A,	   IRF8	   and	   CD226	   (24,	   30-­‐36).	   Collectively,	   these	   studies	  
demonstrate	   a	   heavy	   bias	   towards	   immune-­‐related	   risk	   genes	   and	   thus	   likely	  
importance	  of	  immune-­‐related	  mechanisms	  in	  pathogenesis	  of	  MS.	  
	  
2.3.	  ENVIRONMENTAL	  FACTORS	  IN	  MS	  
There	   is	   a	   distinct	   geographical	   distribution	   of	  MS	  with	   the	   highest	   prevalence	  
being	  observed	  in	  temperate	  latitudes	  and	  in	  the	  western	  hemisphere	  (Figure	  3).	  
Individuals	  who	  migrate	  from	  low-­‐	  to	  high	  prevalence	  regions	  before	  adolescence	  
acquire	  the	  elevated	  risk	  but	  not	  if	  they	  migrate	  later	   in	  life	  (37-­‐39).	  Accordingly,	  
there	   is	   also	  a	   clear	   association	  between	  MS	  and	   lack	  of	   sun	  exposure.	   This	   fits	  
well	  with	  the	  observed	  protective	  association	  of	  high	  vitamin	  D	  levels	  with	  onset	  
of	   MS	   (40).	   Vitamin	   D	   is	   now	   known	   to	   have	   several	   immunomodulatory	  
properties	  (41).	  
	  
Figure 3. Worldwide prevalence of MS per 100,000 inhabitants. Adapted from the World 
Multiple Sclerosis Resource Center, http://www.msrc.co.uk.  
	  
Moreover,	   a	   number	   of	   infectious	   agents	   have	   been	   associated	   with	   MS,	   in	  
particular	  Epstein-­‐Barr	  virus	  (EBV)	  and	  human	  herpes	  virus	  6	  (HHV6)	  (42,	  43).	  They	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have	  been	  reported	  to	  affect	  the	  development	  and	  clinical	  course	  of	  MS	  (44),	  but	  
a	  clear	  association	  with	  a	  particular	  viral	  pathogen	  has	  not	  been	  determined.	  The	  
role	   of	   infectious	   and	   viral	   agents	   in	  MS	   etiology	   and	   pathogenesis	   is	   thus	   still	  
poorly	  understood.	  
Epidemiological	  studies	  also	  establish	  smoking	  as	  a	   risk	   factor	   for	  MS,	  especially	  
when	   interaction	   with	   the	   HLA	   locus	   is	   taken	   into	   account	   (45).	   Interestingly,	  
smoking	  also	  appears	  to	  enhance	  the	  association	  between	  MS	  and	  antibody	  titers	  
to	   EBV	   antigens,	   highlighting	   how	   environmental	   factors	   can	   interact	   to	   affect	  
disease	  (46).	  	  
	  
2.4.	  TREATMENT	  OF	  MS	  
The	   current	   treatments	   for	   MS	   are	   only	   disease-­‐modifying	   and	   do	   not	   cure	  
disease,	  reflecting	  our	  relatively	  poor	  understanding	  of	  the	  disease	  pathogenesis.	  
There	   are	   currently	   two	   first-­‐line	   treatment	   regimens,	   recombinant	   interferon-­‐β	  
(IFNβ)	   and	   the	   polypeptide	   glatiramer	   acetate	   (47).	   In	   addition,	   treatment	  with	  
steroids	   can	   temporarily	   reduce	   ongoing	   symptoms	   (48).	   A	   humanized	  
monoclonal	   antibody,	   Natalizumab,	   directed	   against	   the	   α4-­‐integrin	   of	   the	  
adhesion	  molecule	   very	   late	   activating	   antigen	   (VLA)-­‐4	   on	   leukocytes	   has	  more	  
recently	   emerged	   as	   a	   potent	   disease-­‐ameliorating	   drug	   (49,	   50).	   However,	  
Natalizumab	  has	  also	  been	  associated	  with	  more	  severe	  adverse	  effects	  (47,	  51).	  
Novel	  MS	  drugs	  are	  evaluated	  continuously	  and	  some	  of	  these	  have	  significantly	  
reduced	  disease	  in	  large	  clinical	  trials	  (52-­‐54).	  
	  
2.5.	  GUILLAIN-­‐BARRÉ	  SYNDROME	  
Guillain-­‐Barré	   syndrome	   (GBS)	   is	   an	   inflammatory	   disease	   of	   the	   peripheral	  
nervous	   system	   encompassing	   different	   subtypes,	   with	   acute	   inflammatory	  
demyelinating	  polyradiculoneuropathy	   (AIDP)	  being	   the	  most	  prevalent	   subtype	  
(55).	   In	  AIDP,	  macrophages	   invade	  the	  myelin	  sheaths	  of	  the	  peripheral	  nervous	  
system	   through	   a	   mechanism	   likely	   involving	   activated	   T	   cells	   and	   antibodies.	  
AIDP	   therefore	   shares	   many	   characteristics	   with	   MS.	   Symptoms	   of	   GBS	   are	  
diverse,	   depending	   on	   whether	   sensory,	   motor	   or	   autonomous	   nerves	   are	  
affected,	   but	   typically	   peak	   four	   weeks	   after	   onset.	   Disease	   symptoms	   then	  
resolve	  but	  20%	  of	  patients	  are	  left	  with	  persistent	  and	  significant	  disability	  (55).	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3.	  DISEASE	  MODELS	  
	  
3.1.	  EXPERIMENTAL	  AUTOIMMUNE	  ENCEPHALOMYELITIS	  
The	   most	   common	   animal	   model	   of	   MS	   is	   experimental	   autoimmune	  
encephalomyelitis	   (EAE)	   and	   has	   been	   established	   in	   several	   species	   including	  
rats,	   mice,	   guinea	   pigs,	   marmosets,	   rabbits	   and	   primates	   (56-­‐61).	   EAE	   can	   be	  
induced	   by	   subcutaneous	   injection	   of	   recombinant	   or	   purified	   CNS	   antigens,	  
synthetic	   peptides,	  whole	   CNS	   tissue	   or	   infection	  with	   encephalitogenic	   viruses	  
(62,	   63).	   Depending	   on	   the	   antigen	   and	   genetic	   background,	   these	   models	  
recapitulate	   distinct	   features	   of	   human	  MS,	   both	   regarding	   disease	   course	   and	  
pathogenic	  mechanisms.	  There	  are	  numerous	  CNS	  antigens	  that	  induce	  EAE,	  and	  
three	  of	  them	  have	  been	  used	   in	  my	  thesis.	  The	  most	  extensively	  used	  model	   in	  
my	  studies	  is	  the	  myelin	  oligodendrocyte	  glycoprotein	  (MOG)-­‐induced	  EAE	  model	  
in	   rats,	   which	   appears	   to	   accurately	   reflect	   the	   distinct	   disease	   courses	   of	  MS.	  
MOG-­‐EAE	   is	   characterized	   by	   a	   disease	   onset	   at	   10-­‐14	   days	   post-­‐immunization	  
resulting	   in	   an	   ascending	   paralysis	   with	   periods	   of	   remission	   (64)	   (Figure	   4).	  
Another	   model,	   whole	   spinal	   cord	   homogenate	   (WSC)-­‐induced	   EAE,	   displays	  
similar	  relapsing	  disease	  characteristics	  (63,	  65).	  In	  contrast	  to	  these	  models,	  the	  
myelin	  basic	  protein	  (MBP)-­‐induced	  EAE	  model	  is	  acute	  and	  resolves	  after	  the	  first	  
disease	  bout	  (66).	  This	  classical	  model	  requires	  Mycobacterium	  tuberculosis	  for	  its	  
induction,	  and	  the	  rapid	  disease	  course	  is	  typically	  devoid	  of	  demyelination.	  
EAE	   can	   also	   be	   induced	   passively.	   In	   this	   alternative	   induction	   protocol,	  
autoreactive	  T	  cells	  are	  injected	  intravenously	  or	  intraperitonaelly	  and	  give	  rise	  to	  
a	   transient	   demyelination	   and	   motor	   impairment	   (67).	   Spontaneous	   EAE	   mice	  
models	  also	  exist,	  but	  require	  use	  of	  genetically	  engineered	  strains	  in	  which	  T	  cell	  
receptors	  have	  been	  restricted	  to	  recognize	  CNS	  antigens	  (68,	  69).	  Spontaneous	  
disease	  can	  also	  be	  exacerbated	  by	  introduction	  of	  myelin-­‐specific	  B	  cell	  receptors	  
(70).	  	  	  	  	  	  	  

























































	  	  	  	  	  	  	  	  	  	  	  
 
Figure 4. Representative graphs of the various EAE courses observed in the rat MOG-EAE 
model. The y-axis represents days post-immunization (p.i.). The x-axis represent EAE 
severity, where 0 = no clinical symptoms, 1 = limp tail, 2 = disturbed gait, 3 = complete hind 
leg paralysis, 4 = tetraplegy or moribund, 5 = dead. 
 
Most	   immune	   cells	   have	   been	   attributed	   roles	   in	   EAE	   pathogenesis,	   which	   can	  
explain	  why	  EAE	  has	  been	  extensively	   used	   for	  general	   studies	  of	   inflammation	  
(71).	   For	   this	   reason	  EAE	   is	  occasionally	   criticized	   for	  not	   truly	   representing	  MS,	  
with	  concerns	  that	  some	  therapeutic	  approaches	   in	  EAE	  have	  been	  unsuccessful	  
in	  MS	  (72).	  However,	  a	  positive	  outcome	  to	  a	  given	  treatment	  has	  depended	  on	  
the	  EAE	  model	  employed.	  Indeed,	  most	  approved	  MS	  therapies	  used	  today	  have	  
first	  been	  characterized	  in	  various	  EAE	  models	  (73).	  
	  
3.2.	  GENETICS	  OF	  EAE	  
The	  genetic	   effect	   in	   EAE	   is	   clearly	   established	   as	  different	   strains	  display	  great	  
variation	   in	   disease	   susceptibility	   under	   the	   same	  environmental	   conditions	   (74,	  
75).	  As	  in	  MS,	  the	  MHC	  locus	  is	  the	  major	  genetic	  determinant	  of	  disease	  (76-­‐79).	  
This	  effect	  is	  fairly	  profound	  and	  some	  strains	  carry	  MHC	  haplotypes	  that	  are	  only	  
susceptible	  to	  certain	  CNS	  antigens	  (79).	  However,	  there	  is	  a	  substantial	  non-­‐MHC	  
gene	  contribution	  and	  to	  date,	  at	  least	  50	  genetic	  regions	  are	  known	  to	  regulate	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EAE	   in	   rodents	   (75,	   80-­‐88).	   Successful	   examples	   of	   identifying	   the	   responsible	  
gene	  have	  emerged,	  both	  for	  EAE	  and	  other	  experimental	  disease	  models	  (89-­‐92).	  
Collectively,	   these	   findings	   indicate	   great	   similarities	   in	   genetic	   regulation	  
between	  EAE	  and	  MS.	  Given	  the	  controlled	  environment	  and	  tissue	  availability	  in	  
experimental	   studies,	   candidate	   gene	   investigation	   in	   EAE	   serves	   as	   a	   powerful	  
complement	  to	  analogous	  human	  efforts.	  EAE	  risk	  genes	  can	  be	  translated	  to	  MS	  
risk	  genes	  and	  can	  provide	  valuable	  insight	  into	  the	  origin	  of	  disease	  mechanisms.	  
Gene-­‐gene	  and	  gene-­‐environment	  interactions	  can	  also	  more	  readily	  be	  examined	  
due	   to	   the	   reduced	   variation.	   The	  methods	   employed	   in	   our	   studies	   to	   identify	  
disease	  genes	  in	  rodents	  will	  be	  discussed	  later	  in	  this	  thesis.	  	  
3.3.	  EXPERIMENTAL	  AUTOIMMUNE	  NEURITIS	  
Experimental	   autoimmune	   neuritis	   (EAN)	   is	   a	   model	   of	   GBS	   and	   its	   pathology	  
closely	   resembles	   that	   of	   the	   AIDP	   subtype	   (55).	   EAN	   is	   induced	   in	   a	   similar	  
fashion	   to	   EAE,	   by	   immunization	   of	   peripheral	   myelin	   antigen.	   The	   disease	   is	  
characterized	  by	  a	  CD4+	  T	  cell	  mediated	  response	  specific	  for	  the	  myelin	  proteins	  
P2,	   P0,	   or	   PMP22	   expressed	   on	   Schwann	   cells,	   the	   myelinating	   cells	   of	   the	  
peripheral	   nervous	   system	   (93-­‐95).	   Demyelination	   is	   macrophage-­‐mediated	   but	  
most	   immune	   cells	   are	   likely	   to	   be	   important	   in	   disease,	   as	   seen	   for	   EAE.	   The	  
disease	   onset	   is	   usually	   around	   10-­‐12	   days	   p.i.	   and	   manifests	   as	   an	   ascending	  
paralysis	  with	  pronounced	  gait	  disturbances.	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4.	  THE	  IMMUNE	  SYSTEM	  
	  	  
We	   do	   not	   yet	   fully	   understand	   the	   pathogenic	   mechanisms	   that	   regulate	  MS.	  
What	   is	   clear	   is	   that	   several	   immune	  cells	   and	  pathways	  are	  essential	   in	  disease	  
development,	   a	   notion	   that	   is	   also	   supported	   by	   genetic	   studies.	   Moreover,	  
investigation	   of	   EAE	   pathogenesis	   has	   provided	   important	   insights	   into	   the	  
mechanisms	   underlying	   MS	   (71).	   There	   is	   no	   formal	   proof	   that	   MS,	   and	   many	  
other	  autoimmune	  diseases	  (ADs)	  are	  initiated	  by	  an	  autoimmune	  event.	  The	  term	  
ADs	  will	  therefore	  refer	  to	  the	  downstream	  pathogenic	  mechanisms	  whereby	  self-­‐
tissue	  or	  antigens	  are	  destroyed,	  irrespective	  of	  the	  trigger.	  
Adaptive	   immune	   responses	   have	   for	   a	   long	   time	  been	   in	   focus	   in	  MS	   and	   EAE	  
research,	  with	  the	  notion	  that	  disease	  ensues	  upon	  breakage	  of	  tolerance	  to	  self-­‐
antigens.	  Concordant	  with	  this	  thinking,	  the	  major	  genetic	  risk	  factor	  in	  both	  MS	  
and	   EAE	   is	   the	   HLA/MHC	   locus	   and	   the	   thus	   far	   identified	   non-­‐MHC	   risk	   genes	  
indicate	  a	  role	  for	  adaptive	   immunity	  and,	   in	  particular,	  T	  cells	  (34).	  Additionally,	  
transfer	  of	  T	  cells	  specific	  for	  myelin	  antigens	  is	  sufficient	  to	  induce	  EAE	  (96).	  For	  
these	   reasons,	   the	   importance	   of	   T	   cells	   in	   neuroinflammation	   has	   been	  
intensively	   explored	   and	   many	   studies	   have	   suggested	   that	   T	   helper	   1	   (TH1)	  
polarized	  CD4+	  T	  cells	  are	  important	  in	  MS	  initiation	  (97).	  This	  is	  supported	  by	  an	  
increased	   number	   of	   TH1	   cells	   producing	   IFNγ	   in	   the	   blood,	   cerebrospinal	   fluid	  
(CSF)	   and	   around	   lesions	   of	   patients	   (98-­‐100).	   IFNγ	   is	   the	   TH1	   hallmark	   cytokine	  
with	  many	   pro-­‐inflammatory	   effects,	   including	   activation	   of	  macrophages	   (101).	  
However,	  during	  the	  last	  few	  years	  the	  relative	   importance	  of	  TH1	  cells	  has	  been	  
debated.	   Instead,	   the	   TH17	   subset	   has	   emerged	   as	   an	   important	   mediator	   of	  
disease.	  TH17	  cells	  differ	  from	  TH1	  cells	  in	  their	  cytokine	  profile;	  and	  rather	  secrete	  
IL17,	   IL21,	   IL22	   and	   granulocyte-­‐macrophage	   colony	   stimulating	   factor	   (GM-­‐CSF)	  
(102,	   103).	   It	   is	  noteworthy	   that	  adoptive	   transfer	  of	  either	   subset	  will	   generate	  
EAE,	  albeit	  with	  distinct	  characteristics	  (96,	  104).	  
CD8+	  T	  cells	  have	  been	  relatively	  ignored	  in	  the	  pathogenesis	  of	  MS.	  This	  is	  in	  part	  
due	  to	  the	  stronger	  genetic	  association	  of	  MHC	  class	  II	  alleles	  to	  MS	  compared	  to	  
MHC	  class	  I	  alleles,	  and	  the	  dominance	  of	  CD4+	  T	  cells	  in	  most	  EAE	  models	  (105).	  	  
Conversely,	  CD8+	  T	  cells	  outnumber	  CD4+	  T	  cells	  around	  MS	  lesions	  (106),	  and	  MS	  
therapies	  that	  target	  CD4+	  T	  cells	  have	  been	  unsuccessful	  whereas	  whole	  T	  cell-­‐
depleting	  therapies	  reduce	  disease	  considerably	  (105).	  
B	  cells	  also	  contribute	  to	  disease	  through	  antigen	  presentation	  and	  autoantibody	  
production	   (107,	   108).	   These	   autoantibodies	   appear	   to	   recognize	   large	  
conformational	  epitopes	  rather	  than	  short	  peptides	  (109).	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Adaptive	   immune	   responses	   can	   also	   be	   disease-­‐protective.	   In	   particular,	  
regulatory	   T	   cells	   (TREGS)	  which	   are	   often	   CD4+CD25+Foxp3+,	  maintain	   peripheral	  
tolerance	  by	  suppressing	  autoreactive	  T	  cells	  through	  mechanisms	  involving	  cell-­‐
cell	  contact	  and	  cytokines	  such	  as	  IL10	  and	  TGF-­‐β	  (71).	  Under	  normal	  steady-­‐state	  
conditions	   TREGS	   potently	   inhibit	   excessive	   inflammation.	   Conversely,	   failure	   of	  
TREGS	   to	   curtail	   inflammation	   has	   been	   described	   for	  MS	   as	   TREGS	   from	   patients	  
have	  defective	  suppressive	  capacities	  compared	  to	  those	  of	  healthy	  controls	  (110,	  
111).	  CD8+	  T	  cells	  have	  also	  been	  attributed	  a	  protective	  role	  in	  some	  studies	  (112-­‐
114).	   Similarly,	   other	   reports	   suggest	   an	   additional	   influence	   from	   a	   disease-­‐
ameliorating	  B	  cell	  subset	  (70,	  115,	  116).	  
The	  mechanisms	  mentioned	  so	  far	  primarily	  relate	  to	  antigen-­‐specific	  events,	  but	  
innate	   immune	   cells	   are	   also	   essential	   in	   disease	  development	   and	  progression.	  
These	   innate	   mechanisms	   include	   antigen	   presentation	   to	   lymphocytes	   and	  
various	  responses	  through	  activation	  of	  their	  predetermined	  surface	  receptors.	  	  	  
For	   example,	   dendritic	   cells	   (DCs),	   which	   accumulate	   in	   the	   CNS	   during	  
inflammation,	   are	   professional	   antigen	   presenting	   cells	   (APC)	   and	   potent	  
producers	  of	  both	  pro-­‐	  and	  anti-­‐inflammatory	  cytokines.	  As	  such,	  DCs	  play	  a	  major	  
role	  in	  determining	  the	  activation	  and	  differentiation	  of	  naïve	  T	  cells	  into	  effector	  
or	  suppressive	  cells	  (117,	  118).	  	  
Microglia	   and	   macrophages	   likely	   contribute	   to	   disease	   through	   similar	  
mechanisms.	   The	   two	  cell	   types	   share	  many	   features,	   including	  phagocytosis	  of	  
surrounding	   cells	   and	   tissue,	   cytokine	  production	   and	  antigen	  presentation,	   but	  
they	  differ	  in	  their	  tissue	  distribution	  (119).	  Microglia	  are	  CNS-­‐resident	  cells,	  where	  
they	   are	   the	  most	   common	   immune	   cells.	  Macrophages	   infiltrate	   the	   CNS	   from	  
the	   periphery.	   During	   MS,	   phagocytosing	   microglia	   and	   macrophages	   are	  
primarily	  responsible	  for	  the	  CNS	  tissue	  destruction	  (120).	  
Another	   innate	  cell	  mechanism	   involves	  natural	  killer	   (NK)	  cells	  which	  appear	   to	  
be	  mainly	  disease-­‐protective	   in	  MS	  and	  EAE	  (121,	  122).	  Decreased	  numbers	  of	  NK	  
cells	  have	  been	  detected	  in	  MS	  patients	  and	  depletion	  of	  NK	  cells	  in	  EAE	  leads	  to	  
increased	  severity	  (71).	  
Many	  more	  cell	  types	  are	  implicated	  in	  the	  pathogenesis	  of	  MS	  and	  EAE,	  including	  
mast	   cells	   (123),	   γδ	   T	   cells	   (124)	   and	   NKT	   cells	   (125).	   The	   interactions	   between	  
these	   cells	   are	   poorly	   defined	   and	   future	   studies	   will	   hopefully	   further	   our	  
understanding	  of	  the	  molecular	  events	  that	  trigger	  and	  sustain	  disease.	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4.1.	  CYTOKINES	  AND	  RECEPTORS	  
Cytokines	  and	  receptors,	  which	  comprise	  several	  heterogeneous	  subgroups,	  have	  
frequently	  been	  studied	   in	  my	  thesis.	   In	  particular,	   the	  cytokines	  tumor	  necrosis	  
factor	   (TNF),	   IFNγ	   and	   IL22	   and	   their	   receptors	   have	   been	   of	   interest.	   During	  
disease	  initiation	  in	  the	  MOG-­‐EAE	  model,	  all	  three	  cytokines	  are	  upregulated	  in	  the	  
susceptible	   Dark	   Agouti	   (DA)	   rat	   strain	   compared	   to	   the	   resistant	   Piebald	   Viral	  
Glaxo	   (PVG)	   strain	  which	  may	   indicate	  an	  enhanced	  differention	  of	  TH1	  and	  TH17	  
effector	   cells	   (126).	   In	   the	   WSC-­‐EAE	   model,	   IFNγ	   and	   TNF	   expression	   in	   CNS	  
infiltrating	  cells	  correlates	  with	  disease	  symptoms	  (127,	  128),	  and	  this	  expression	  is	  
MHC-­‐haplotype	   dependent	   (77).	   This	   section	   will	   illustrate	   examples	   of	   the	  
pluripotent	  and	  sometimes	  opposing	   roles	   these	  secreted	  molecules	  can	  play	   in	  
shaping	  the	  immune	  response.	  	  
Tumor	   necrosis	   factor	   (TNF)	   is	   rapidly	   produced	   upon	   infection	   to	   confer	  
immunity	   to	   the	   host.	   TNF	   regulates	   several	   biological	   processes	   including	  
inflammation,	   apoptosis	   and	   cellular	   expansion	   (129),	   Both	   soluble	   and	  
membrane-­‐bound	   forms	   of	   the	   cytokine	   exist	   with	   the	   ability	   to	   bind	   several	  
distinct	  receptors	  (130-­‐133).	  Elevated	  TNF	  expression	  is	  observed	  in	  inflammatory	  
disorders	  such	  as	  MS,	  RA	  and	  septic	  shock	  (134-­‐136),	  whereas	  reduced	  TNF	  levels	  
associate	  with	  increased	  risk	  of	  infections	  (137).	  
Moreover,	  TNF-­‐blocking	  agents	  potently	  reduce	  severity	  of	  several	  ADs	  (138,	  139).	  
By	   contrast,	   similar	   TNF-­‐depletion	   in	   MS	   patients	   worsens	   disease	   symptoms	  
demonstrating	   how	   blocking	   TNF	   is	   not	   always	   beneficial	   (140).	   The	   disparate	  
functions	  of	  TNF	  may	  be	  partly	  attributed	  to	  the	  diverse	  functions	  of	  its	  receptors	  
(141-­‐143).	  	  
IFNγ,	  mainly	  produced	  by	  T	  cells	  and	  NK	  cells	  (144),	  is	  another	  cytokine	  displaying	  
opposing	   roles	   in	   autoimmunity.	   On	   one	   hand,	   IFNγ	   drives	   inflammation	   by	  
increasing	   TH1	   differentiation	   and	   enhancing	   MHC	   expression	   and	   activation	   of	  
innate	  immune	  cells	  (144-­‐147).	  Accordingly,	  treatment	  of	  MS	  with	  IFNγ	  worsened	  
disease	   symptoms	   (148).	   On	   the	   other	   hand,	   IFNγ	   and	   IFNγ	   receptor	   knockout	  
strains	  convert	  EAE-­‐resistant	  mice	  to	  a	  susceptible	  phenotype	  (149-­‐151).	  	  
IL22	  is	  a	  cytokine	  that	  associates	  with	  CD	  and	  psoriasis	  (152,	  153).	  Different	  subsets	  
of	   immune	   cells	   excrete	   IL22,	  with	   TH17	   cells	   being	   the	   primary	   producers	   (154-­‐
157).	   	   In	   addition,	  one	   report	   suggests	   that	  monocytes	   can	   also	  produce	   IL22	   in	  
presence	  of	  IL23	  and	  lipopolysaccharide	  (LPS)	  (152).	  Its	  surface	  receptor,	  IL22R1,	  is	  
expressed	  on	  a	  variety	  of	  epithelial	  tissues	  (158).	  The	  IL22	  system	  also	  consists	  of	  a	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soluble	   receptor,	   IL22R	   alpha	   2	   (IL22RA2),	   with	   relatively	   unknown	   function	   in	  
biology	  (159,	  160).	  	  
These	  examples	   illustrate	   that	   in	  order	   to	   fully	  understand	  cytokines’	   impact	  on	  
disease	  one	  must	  determine	  their	  cellular	  source	  as	  well	  as	  temporal	  and	  spatial	  
expression	  of	  the	  cytokine	  and	  the	  corresponding	  receptors.	  	  
	  
	  
4.2.	  SHARED	  IMMUNE	  MECHANISMS	  
ADs	  encompass	  disorders	  such	  as	  MS,	  GBS,	  CD,	  T1D	  and	  rheumatic	  diseases	  such	  
as	  RA	  and	  systemic	  lupus	  erythematosus	  (SLE).	  They	  all	  have	  in	  common	  that	  the	  
immune	  system	  attacks	  self	  tissues	  or	  antigens.	   It	   is	  also	   likely	  that	  their	  disease	  
pathways	   converge	   in	   part	   into	   key	   endpoint	  mechanisms.	   If	   such	  mechanisms	  
were	  genetically	  determined,	  we	  would	  expect	  ADs	  to	  cluster	  in	  families	  at	  higher	  
risk.	   Although	   some	   debate	   surrounds	   this	   hypothesis,	   larger	   population-­‐based	  
surveys	   demonstrated	   that	   families	   with	  members	   affected	   by	   RA	   or	  MS	  were	  
more	  likely	  to	  also	  manifest	  other	  ADs	  (161,	  162).	  The	  frequency	  of	  AD	  aggregation	  
was	  higher	  in	  families	  containing	  multiple	  members	  with	  MS	  compared	  to	  families	  
with	  a	  single	  member	  affected	  by	  MS	  (162).	  Several	  genetic	  studies	  support	  this	  
notion,	  with	  existing	  reports	  on	  shared	  risk	  genes	  between	  ADs,	   including	   IL2RA	  
and	  CLEC16A	  for	  MS	  and	  T1D	  and	  PTPN22	  for	  RA,	  T1D	  and	  SLE	  (163,	  164).	  	  
While	   strongly	   support	  a	  partially	   common	  basis	   for	  ADs	   these	   findings	   suggest	  
that	   distinct	   alleles	   and	   possibly	   mechanisms	   control	   distinct	   ADs,	   with	   little	  
overlap	  in	  between.	  In	  this	  thesis,	  shared	  genetic	  regulation	  has	  been	  investigated	  
with	  the	  aim	  of	  identifying	  shared	  pathways.	  Shared	  pathways	  may	  implicate	  for	  
example	   TREG	   activity	   or	   elevated	   pro-­‐inflammatory	   cytokine	   levels	   such	   as	   TNF	  
and	   IFNγ.	   In	   experimental	   models	   of	   ADs,	   several	   shared	   genetic	   regions	   have	  
been	  reported,	  making	  them	  highly	  suitable	  for	  this	  purpose	  (165).	  
When	   successful,	   this	   approach	   will	   facilitate	   treatment	   against	   pathways	  
controlling	  distinct	  diseases,	   irrespective	  of	   the	  exact	  polymorphisms	   regulating	  
them.	  For	  example,	  TRAF1C-­‐5	  and	  TNFSF15,	  which	  both	  implicate	  a	  role	  in	  disease	  
for	  TNF,	  are	  risk	  genes	  for	  RA	  and	  CD,	  respectively	  (166,	  167).	  In	  analogy	  with	  this,	  
TNF-­‐blockade	  is	  a	  successful	  treatment	  of	  both	  diseases	  (138,	  139).	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5.	  AIMS	  OF	  MY	  THESIS	  
	  
This	   thesis	   focuses	   on	   dissecting	   and	   understanding	   genetic	   regulation	   of	  
complex	  inflammatory	  diseases.	  I	  used	  an	  unbiased	  approach	  to	  identify	  disease-­‐
regulating	   genes	   in	   experimental	  models	   of	   two	   human	   diseases:	  MS	   and	   GBS.	  
The	  specific	  aims	  of	  my	  thesis	  are	  categorized	  as	  follows:	  
	  
	  
1) Position	   disease	   risk	   genes	   in	   experimental	   neuroinflammation	   and	  
translate	  findings	  to	  human	  disease.	  
	  
	  
2) Define	  the	  pathogenic	  mechanisms	  controlled	  by	  these	  genes.	  
	  
	  
3) Identify	  shared	  mechanisms	  across	  autoimmune	  diseases.	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6.	  METHODOLOGY	  
6.1.	  FINDING	  RISK	  GENES	  IN	  HUMANS	  
The	   identification	   of	   disease-­‐regulating	   gene	   variants	   has	   proven	   difficult.	   The	  
relatively	   small	   effect	   exerted	   by	   the	   risk	   genes	   has	   been	   one	   issue.	   Another	  
obstacle	  is	  the	  failure	  to	  reach	  statistical	  power	  capable	  of	  addressing	  the	  genetic	  
heterogeneity	  and	  confounding	  factors,	  including	  environment,	  that	  are	  inherent	  
to	  complex	  human	  disorders.	  Traditionally,	  linkage	  mapping	  -­‐	  where	  we	  follow	  the	  
inheritance	  of	  a	  disease	  with	  a	  marker	  linked	  to	  the	  risk	  gene	  -­‐	  has	  been	  used	  to	  
identify	  disease	  genes.	  Similar	  studies	  in	  complex	  diseases	  can	  offer	  an	  advantage	  
in	   identifying	   rare	   risk	   variants	   that	   aggregate	   in	   some	   families,	   but	   thus	   far	  
linkage	  studies	  have	  mostly	  proven	  fruitful	  for	  monogenic	  diseases.	  In	  MS,	  several	  
linkage	   analyses	   have	   failed	   to	   accurately	   detect	   any	   non-­‐HLA	   risk	   loci	   (22,	   168-­‐
174).	  The	  obstacles	   include	  too	  weak	  or	   inconsistent	  statistical	  signals,	  and	  poor	  
resolution	  due	  to	  an	  inadequate	  number	  of	  families	  being	  included	  (22).	  For	  these	  
reasons,	  the	  only	  region	  unequivocally	  linked	  to	  MS	  was	  for	  long	  the	  HLA,	  due	  to	  
its	  major	  genetic	  effect	  represented	  by	  an	  increased	  relative	  disease	  risk,	  or	  odds	  
ratio	  (OR)	  of	  approximately	  3	  (18,	  19,	  28,	  175).	  	  
Instead,	   technical	   advantages	   in	   genotyping	   and	   the	   sequencing	   of	   the	   human	  
genome	  have	  enabled	  use	  of	  genome-­‐wide	  association	  scans	  (GWAS)	  of	  complex	  
diseases.	   In	   an	   association	   study,	   a	   vast	   amount	   of	   genetic	   markers	   (into	   the	  
millions)	   located	  throughout	  the	  genome	  are	  tested	   in	  a	  case-­‐control	  cohort	   for	  
association	  to	  disease.	  The	  association	  is	  then	  performed	  by	  comparing	  frequency	  
of	  each	  marker,	  or	  allele,	  between	  cases	  and	  controls.	  The	  markers	  are	   typically	  
single	   nucleotide	   polymorphisms	   (SNPs),	   but	   more	   recent	   GWAS	   also	   include	  
larger	  variations,	  such	  as	  copy	  number	  variations	  (CNVs)	  (176).	  When	  adequately	  
powered,	  GWAS	  have	  identified	  several	  risk	  genes	  (30,	  34,	  163,	  166,	  167,	  177,	  178).	  
The	   number	   of	   required	   cases	   and	   controls	   in	   GWAS	   depends	   largely	   on	   the	  
expected	   effects	   and	   frequency	   of	   the	   risk	   genes	   (14).	   So	   far,	   most	   identified	  
common	  disease	  risk	  alleles	  display	  weak	  ORs,	   increasing	  the	  relative	  risk	  with	  a	  
factor	  of	  less	  than	  1.5	  (179).	  Typically,	  several	  thousands	  of	  cases	  and	  controls	  are	  
necessary	  for	  a	  reliable	  investigation	  (14,	  177).	  On	  the	  other	  hand,	  this	  means	  that	  
even	  larger	  GWAS	  hold	  the	  potential	  to	  discover	  genes	  with	  very	  small	  effects.	  
One	   assumption	   in	   the	   design	   of	   association	   studies	   is	   that	   a	   large	   part	   of	   the	  
genetic	   variation	   controlling	   disease	   resides	   in	   common	   gene	   variants.	   This	   is	  
referred	   to	   as	   the	   common-­‐disease	   common-­‐variant	   (CDCV)	   hypothesis	   (2),	  
whereby	  several	  common	  alleles	  each	  contribute	  to	  disease	  with	  weak	  effects.	  A	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common	   allele	   is	   typically	   defined	   as	   having	   a	  minor	   allele	   frequency>1%	   in	   the	  
population	  (180).	  This	   rationale	  has	  been	  essential	   for	  the	   International	  Hapmap	  
project,	  in	  which	  several	  reference	  individuals	  in	  search	  for	  common	  variations,	  or	  
single	  nucleotide	  polymorphisms	   (SNPs)	  have	  been	  mapped	  across	   the	  genome	  
(180).	   SNPs	   that	   are	   in	   high	   linkage	   disequilibrium	   (LD)	   are	   then	   selected.	   LD	  
refers	  to	  the	  non-­‐random	  co-­‐occurance	  of	  two	  loci	  during	  recombination	  (181).	  A	  
high	  degree	  of	  LD	  between	   two	  SNPs	   therefore	   indicates	   that	   they	  are	   likely	   to	  
co-­‐segregrate.	   By	   selecting	   such	   SNPs,	   also	   called	   tagging	   SNPs,	   most	   of	   the	  
genetic	  variation	  can	  be	  captured	  with	  a	  limited	  number	  of	  markers.	  	  
An	   opposing	   hypothesis	   to	   CDCV	   is	   that	   disease	   is	   instead	   regulated	   by	   rare	  
mutations	   conferring	   relatively	   strong	  effects.	  By	  default,	   such	  variations	  would	  
be	  difficult	  to	  identify	  relying	  on	  conventional	  association	  studies.	  It	   is	   likely	  that	  
common	  disorders	  arise	  by	  a	  combination	  of	   these	   two	  scenarios	   (182-­‐184).	  The	  
GWAS	   of	   MS	   performed	   to	   date	   have	   provided	   the	   power	   and	   resolution	   to	  
identify	   some	   non-­‐MHC	   risk	   genes	   (30,	   34).	   Future	   studies	   with	   even	   larger	  
cohorts	  are	  likely	  to	  identify	  more	  variants.	  	  
Another	  problem	  is	  why	  the	  identified	  risk	  genes	  typically	  combine	  to	  only	  explain	  
fractions	   of	   the	   genetic	   variance.	   One	   reason	   for	   this	   may	   be	   the	   largely	  
undiscovered	  epistatic	   interactions	  between	   loci	  across	  the	  genome.	  Epistasis	   in	  
this	   context	   refers	   to	   the	   effect	   of	   one	   gene	   being	   dependent	   on	   another	   (or	  
several	   other)	   genes	   (185).	   Studying	   epistasis	   in	   complex	   diseases	   has	   proven	  
difficult	   with	   few	   successful	   examples,	   all	   providing	   limited	   functional	   insights	  
(186-­‐188).	   Remaining	   obstacles	   include	   the	   need	   for	   better	   understanding	   the	  
functional	   relevance	   of	   these	   polymorphisms.	   This	   is	   largely	   due	   to	   tissue	  
inaccessibility,	   although	   some	   disease-­‐relevant	   material	   can	   be	   collected.	  
Examples	   of	   this	   are	   peripheral	   blood	   and	   cerebrospinal	   fluid	   (CSF)	   in	   which	  
transcript	  levels	  of	  risk	  genes	  can	  be	  correlated	  with	  specific	  genotypes.	  	  
	  
6.2.	  FINDING	  RISK	  GENES	  IN	  RODENTS	  
Genetic	  studies	   in	  experimental	  models	  of	  MS	  hold	  the	  advantage	  of	  controlling	  
environmental	   factors,	  minimal	  heterogeneity	  by	  use	  of	   inbred	  strains	  and	   large	  
study	   cohorts	   providing	   sufficient	   power	   to	   identify	   low-­‐risk	   alleles	   (75).	   The	  
tissue	  availability	  and	  possibility	   to	  generate	   recombinant	   strains	  offer	  powerful	  
tools	  that	  can	  confirm	  the	  discovered	  genetic	  influences.	  
The	   typical	   approach	   is	   to	   perform	   linkage	   studies	   in	   rodents	   with	   opposing	  
disease	   susceptibilities,	   in	   our	   case	   EAE	   in	   rats	   (81,	   84,	   189).	   By	   crossing	   EAE-­‐












susceptible	  and	  resistant	  strains	  we	  can	  obtain	  genetically	  unique	  individuals	  and	  
the	  disease	  pre-­‐disposition	  for	  each	   individual	  will	  depend	  on	  which	  alleles	  were	  
inherited.	   This	   is	   first	   performed	   in	   an	   intercross	   (F2	   or	   backcross	   (N2),	   where	  
genetic	  regions,	  or	  quantitative	  trait	   loci	   (QTLs)	  and	  their	  relative	  effects	  can	  be	  
determined	  across	  the	  genome	  (Figure	  5).	  	  
Although	   practical	   in	   initial	   identification	   of	   broad	   QTLs,	   F2	   crosses	   have	   their	  
limitations.	   The	   QTLs	   identified	   in	   F2	   crosses	   typically	   comprise	   hundreds	   to	  
thousands	   of	   genes	   and	   this	   hampers	   candidate	   gene	   investigation.	   Moreover,	  
large	  QTLs	  can	  in	  fact	  harbor	  several	  QTLs	  that	  may	  or	  may	  not	  interact	  with	  each	  
other	  (190).	  To	  address	  these	  issues	  one	  can	  generate	  an	  advanced	  intercross	  line	  
(AIL)	  between	  susceptible	  and	  resistant	  strains	  by	  randomly	   intercrossing	  the	  F2	  














Figure 5. Various rodent crossing strategies. An F1 progeny is first generated from EAE-
susceptible and EAE-resistant parental strains. By crossing F1 individuals we then obtain the 
F2 intercross. Alternatively, a backcross (N2) is generated by crossing F1 individuals with 
either of the parental strains. Congenic lines are created similarly, by backcrossing and 
selecting for the region of interest. AILs are produced by intercrossing F2 individuals for 
several generations. 
 
The	  greater	  number	  of	   recombination	  events	   in	   an	  AIL	  enables	   fine-­‐mapping	  of	  
QTLs	   originally	   detected	   in	   F2	   crosses	   (Figure	   6).	   Compared	   with	   an	   F2,	   an	   G10	  










yields	   a	   5-­‐fold	   reduction	   of	   the	   QTL	   interval	   (191).	   This	   provides	   high	   mapping	  
resolution,	   identification	   of	   clustered	   QTLs	   within	   a	   broad	   QTL	   and	   better	  








Figure 6. Refinement of QTL and candidate gene lists by using AIL compared to F2 
intercrosses or backcrosses. The number of candidate genes within the QTL is reduced using 
this strategy. Gray bar represents the narrowed confidence interval 	  
Mapping	   in	  rodent	   intercrosses	  provide	  us	  with	  statistical	   linkage	  of	  a	  candidate	  
gene	   region,	   which	   in	   a	   best-­‐case	   scenario	   contains	   10-­‐20	   genes.	   However,	   to	  
confirm	  this	  linkage	  biologically	  and	  to	  investigate	  the	  functional	  role	  of	  the	  genes	  
within	   the	  QTL,	   congenic	   lines	  are	  often	  created	   (Figure	  5).	   In	   these,	   the	  alleles	  
from	   the	   resistant	   strain	   comprising	   the	  QTL	   are	   introgressed	   onto	   the	   genetic	  
background	   of	   the	   susceptible	   strain,	   or	   vice	   versa	   (192).	  We	   can	   here	   perform	  
functional	   investigation	   of	   the	   QTL	   in	   isolation,	   providing	   a	   permanent	   tool	   for	  
future	  experiments.	  Congenic	  and	  AIL	  breeding	  can	  successfully	  be	  conducted	  in	  
parallel,	   based	   on	   previous	   reports	   in	   F2	   intercrosses	   or	   backcrosses.	  
Accompanying	  AIL	  analysis	  will	  more	  rapidly	  guide	  the	  congenic	  breeding	  towards	  
the	   specific	   region	   of	   relevance.	   Through	   guided	   functional	   experiments	   in	  
congenic	   lines	   the	   importance	   of	   each	   candidate	   gene	   can	   then	   be	   assessed.	  
When	  an	  EAE	  risk	  gene	   is	   finally	   identified	   it	  can	  be	  tested	  for	  association	   in	  MS	  
cohorts	  (Figure	  7).	  	  
	  
6.3.	  LINKAGE	  ANALYSIS	  
With	   linkage	  analysis	  we	  aim	   to	   link	  our	   trait	   (often	  disease)	  with	   the	  genotype	  
(DNA	  marker).	  We	   typically	   use	   interval	  mapping,	  which	   includes	   the	   genotype	  
effect	   both	   at	   and	   between	   the	  markers	   analyzed.	   It	   is	   a	   powerful	  method	   for	  
estimating	   the	  QTL	   location,	   as	   the	  underlying	  variation	   can	   reside	   far	   from	   the	  
genotyped	   DNA	   marker.	   In	   interval	   mapping,	   multiple	   markers	   are	   analyzed	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simultaneously	   and	   the	   genotypes	   between	   are	   predicted	   depending	   on	   the	  
recombination	  frequency	  (193,	  194).	  
	  
The	  significance	  of	  the	  linkage	  is	  displayed	  as	  the	  logarithm	  of	  odds	  (LOD).	  A	  LOD	  
score	  describes	  the	  likelihood	  of	  QTL	  presence	  given	  the	  data	  available	  compared	  
to	   the	   likelihood	  of	  no	  QTL	  presence,	  given	  as	   log	  value	  with	   the	  base	  of	   10.	  To	  
illustrate	  this,	  a	  QTL	  displaying	  linkage	  to	  disease	  with	  a	  LOD	  score	  of	  4.0	  is	  10,000	  
times	  more	   likely	   to	  be	   truly	   linked	   than	  not	   (at	   the	  given	  marker).	   The	   linkage	  
studies	  in	  Papers	  I,	  III	  and	  IV	  were	  conducted	  using	  the	  R/qtl	  software	  (195).	  
	  
We	  establish	  confidence	  intervals	  (CI)	  in	  order	  to	  estimate	  the	  likely	  location	  of	  a	  
QTL.	  A	  95-­‐percent	  CI	  means	  that	  there	  is	  a	  0.95	  probability	  that	  the	  true	  location	  
of	   the	  QTL	   is	  within	   the	  boundaries	  of	   the	  CI.	   In	  papers	   I,	   III	   and	   IV,	   the	  CI	  was	  
determined	   by	   first	   using	   a	   LOD	   drop	   of	   1.8	   (196),	   and	   then	   using	   the	   flanking	  
marker	  as	  boundaries.	  	  
	  	  	  	  	  	  	   	  
Figure 7. Summary of our translational forward genetics approach. Disease-regulating QTLs 
are first dissected in intercrosses (1,2) and confirmed in congenic lines (3). Through sub-
congenization and guided experiments, a few candidate genes can be selected (4). These 
candidates can be further studied functionally in the congenic lines (5), and also be translated 
to MS risk genes in multiple cohorts (6). 
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6.4.	  IMPORTANT	  VARIABLES	  	  
The	  positional	  cloning	  of	  a	  gene	  underlying	  a	  disease	  trait	  in	  experimental	  models	  
is	   often	   a	   time-­‐consuming	   process,	   especially	  when	   using	   an	   unbiased,	   forward	  
genetics	   approach.	   The	   timeline	   for	   the	   initial	   intercross	   mapping	   is	   rather	  
constant,	  although	  advances	  in	  SNP	  identification	  in	  rats	  will	  offer	  large	  arrays	  as	  
alternatives	  to	  conventional	  microsatellite	  genotyping	  (197).	  
It	   is	  rather	   in	  the	  fine-­‐mapping	  of	  the	  candidate	  gene	  where	  most	  time	   is	  spent.	  
Narrowing-­‐down	   a	   QTL	   typically	   involves	   sub-­‐congenization,	   aiming	   at	   isolating	  
the	   disease-­‐regulating	   gene.	   The	   timeline	   of	   this	   depends	   on	   several	   factors,	  
including:	  
 The	  variation	  of	  the	  trait	  
 Strength,	  or	  dominance,	  of	  the	  gene’s	  influence	  on	  the	  trait	  
 Gene	  density	  within	  the	  QTL	  
 Clustering	  of	  related	  genes	  within	  the	  QTL	  
 Rate	  of	  recombination	  in	  the	  region	  
The	  disease	  variation	  in	  EAE	  is	  substantial,	  as	  for	  most	  models	  of	  complex	  disease.	  
This	   is	   largely	   due	   to	   environmental,	   technical	   factors	   and	   the	   numerous	  
redundant	  immune	  mechanisms	  that	  can	  potentially	  override	  the	  influence	  from	  a	  
particular	   candidate	   gene.	   As	   a	   consequence,	   the	   effect	   of	   the	   candidate	   gene	  
(i.e.	   the	  genetic	  variation	   regulating	  disease)	  must	  be	  strong	  enough	   to	  surpass	  
this	  ‘noise	  threshold’.	  
Another	   important	   consideration	   is	   the	   genetic	   architecture	   of	   the	   QTL.	   Gene-­‐
dense	  regions	  are	  more	  difficult	  to	  study,	  as	  minimal	  congenics	  (<1	  Megabase)	  are	  
required	   to	   fully	  exclude	  non-­‐disease	   regulating	  genes.	   In	  addition,	  clustering	  of	  
functionally	   related	   genes,	   e.g.	   cytokines,	   chemokines	   and	   receptors,	   makes	   it	  
difficult	  to	  tailor	  assays	  to	  target	  a	  specific	  gene,	  as	  the	  phenotypic	  read-­‐out	  will	  
likely	  lay	  downstream	  of	  several	  genes	  within	  the	  QTL.	  For	  all	  these	  reasons,	  true	  
positional	  cloning,	  meaning	  the	  isolation	  of	  the	  disease-­‐regulating	  polymorphism,	  
is	   extremely	  difficult	   and	   time-­‐consuming.	  However,	  detailed	   characterization	   in	  
the	  congenic	  line	  can	  identify	  the	  disease	  mechanism	  without	  knowing	  the	  exact	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6.5.	  WHAT	  IS	  THE	  RELEVANT	  PHENOTYPE?	  
When	   conducting	   linkage	   studies	   in	   experimental	   models	   of	   complex	   diseases,	  
the	   penetrance	   of	   the	   gene	   of	   interest	   is	   important.	   This	   is	   also	   true	   for	   the	  
follow-­‐up	   functional	   studies	   in	   congenic	   lines.	   For	   example,	   if	   the	   phenotype	   is	  
EAE	  severity,	   the	  underlying	  genetic	  variation	  has	  to	  be	  strong	  enough	  to	  cause	  
significant	   differences	   in	   EAE	   severity	   between	   individuals	   who	   are	   carriers	   of	  
different	  alleles	  in	  order	  to	  be	  identified.	  	  Sometimes	  this	  is	  not	  the	  case	  as	  other	  
genes	  might	   regulate	  disease	  at	  various	   levels	  and	   ‘override’	   the	  genetic	  variant	  
we	  are	   studying.	   In	   this	   scenario	  we	  would	  not	  observe	   linkage,	  as	   the	  effect	   is	  
too	  weak	   to	   detect.	   One	  way	   to	   overcome	   this	   potential	   obstacle	   is	   to	   have	   a	  
sufficient	  number	  of	  experimental	  animals,	  well	  powered	  enough	  to	  handle	   this	  
complexity	  of	  the	  genetic	  regulation.	  	  
However,	  it	  is	  also	  possible	  to	  use	  other	  phenotypes	  that	  lie	  more	  proximal	  to	  the	  
genetic	   variation.	   If	   clinical	   disease	   represents	   the	   ultimate	   end-­‐point	   read-­‐out,	  
measurement	  of	  protein	  levels	  or	  mRNA	  transcript	  levels	  would	  constitute	  earlier	  
events.	  This	  can	  for	  example	  be	  secretion	  of	  an	  inflammatory	  cytokine	  by	  T	  cells	  
or	   macrophages.	   The	   advantage	   here	   is	   that	   the	   phenotype	   is	   less	   complex	  
resulting	  in	  a	  stronger	  correlation	  between	  the	  genotype	  and	  the	  phenotype.	  One	  
must	  of	  course	  bear	  in	  mind	  that	  such	  phenotypes	  can	  merely	  be	  associated	  with	  
disease	  and	  may	  not	  actually	  be	  disease-­‐causing.	  We	  can	  minimize	  this	  risk	  by	  only	  
studying	   disease-­‐relevant	   tissues	   and	   time	   points	   that	   correlate	   with	   clinical	  
disease.	   In	   the	   studies	   included	   in	   this	   thesis	  we	   have	   used	   clinical	   phenotypes	  
such	   as	   disease	   severity	   and	   susceptibility.	   Simpler	   cellular	   phenotypes	   include	  
lymphocyte	   activation	   upon	   receptor	   stimulation	   and	   CNS	   infiltration.	   This	   will	  
also	  logically	  affect	  protein	  and	  mRNA	  levels	  such	  as	  autoantibody	  titers,	  cytokine	  
secretion	   or	   transcript	   levels	   of	   inflammatory	   genes.	   An	   interesting	  mechanism	  
that	   is	   receiving	   increasing	   attention	   is	   the	   epigenetic	   regulation	   of	   complex	  
diseases.	   	   Epigenetic	   mechanisms	   can	   involve	   DNA	   methylation,	   histone	  
modifications,	   non-­‐coding	   RNAs	   such	   as	   micro	   RNAs	   (miRNA).	   All	   these	  
mechanisms	   will	   affect	   all	   the	   above-­‐mentioned	   events	   (198-­‐202).	   Our	   studied	  
phenotypes	   are	   summarized	   in	   Figure	   8,	   also	   illustrating	   the	   complexity	   of	  
identifying	  natural	  gene	  variants	  that	  regulate	  clinical	  disease.	  	  







































Figure 8. Schematic overview of levels of phenotypes studied in this thesis, ranging from 
clinical symptoms to transcript expression. 
	  
6.6.	  THE	  -­‐OMICS	  ERA	  
Microarray	   technologies	   are	   increasingly	   being	   employed	   in	   applications	   of	  
complex	  diseases.	  For	  genotyping	  it	  has	  been	  essential	  in	  designing	  GWAS	  studies	  
and	  will	  be	  crucial	  in	  analogous	  experimental	  efforts	  (203,	  204).	  At	  the	  messenger	  
RNA	  (mRNA)	  level	  microarrays	  enable	  studies	  of	  whole	  networks	  of	  transcription,	  
including	   correlation	   of	   disease-­‐relevant	   genes	   and	   enrichment	   for	   transcripts	  
regulating	  distinct	  disease	  mechanisms	   (205,	   206).	  This	   regulation	  of	  expression	  
can	   be	   characterized	   by	   expression	   QTL	   (eQTL)	   mapping,	   where	   genome-­‐wide	  
expression	   levels	   are	   tested	   for	   linkage	   to	   genetic	   loci.	   The	   approach	   has	  
successfully	  facilitated	  identification	  of	  several	  genes	  and	  pathways	  important	  for	  
complex	  disease	  (207-­‐209).	  Similar	  profiling	  of	  the	  proteome	  and	  epigenome	  has	  
also	   been	   conducted	   (210,	   211).	   When	   such	   studies	   are	   combined	   with	  
conventional	   linkage	   or	   association	   mapping,	   we	   will	   be	   able	   to	   study	   whole	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disease	  pathways,	  not	  confining	  to	  only	  studying	  candidate	  genes	  in	  isolation.	  This	  
will	   likely	  shed	  new	  light	  on	  the	  complex	  pathogenesis	  underlying	  MS	  and	  other	  
diseases.	  	  	  
	  
6.7.	  WHY	  STUDY	  MS	  USING	  RATS?	  
The	   laboratory	   rat	   (Rattus	   norvegicus)	   has	   long	   been	   employed	   as	   a	   tool	   for	  
establishing	   models	   of	   human	   disease	   (197,	   204).	   	   Reasons	   for	   this	   include	  
facilitated	  analysis	  at	  organ	  and	  cellular	  levels	  because	  of	  the	  rat’s	  larger	  size,	  and	  
generally	  strong	  similarity	  with	  human	  disease.	  Accordingly,	  EAE	   is	  a	  model	   that	  
displays	   several	   disease	   characteristics	   more	   similar	   to	   MS	   compared	   to	   the	  
mouse.	  There	  is	  also	  a	  high	  degree	  of	  genetic	  similarity	  between	  MS	  and	  rat	  EAE,	  
with	   several	   MS	   risk	   genes	   being	   differentially	   expressed	   between	   EAE-­‐
susceptible	  and	   resistant	  EAE	   rat	   strains	   (126).	  Another	   strong	  advantage	   in	   the	  
context	   of	   EAE	   is	   the	  milder	   disease	   induction	   protocol	   for	  most	   rat	   strains.	   It	  
does	   not	   require	   use	   of	   Complete	   Freunds	   Adjuvant	   (CFA)	   or	   pertussis	   toxin,	  
which	   is	  common	  for	  many	  mouse	  EAE	  protocols.	  This	   is	  of	  high	  significance	  for	  
linkage	   studies	   of	   inflammatory	   diseases,	   as	   introduction	   of	   mycobacteria	   or	  
toxins	  will	  themselves	  generate	  specific	  responses	  that	  are	  genetically	  regulated.	  
This	   can	  generate	   statistically	   significant	   linkage	  peaks	   that	   are	  not	   ‘true’	  peaks	  
arising	  from	  the	  autoantigen	  (212).	  
Conversely,	   genetic	   studies	   in	   the	   rat	   have	   suffered	   from	   shortage	  of	   tools	   and	  
the	   genetically	   engineered	   strains	   that	   are	   available	   in	   mice.	   This	   is,	   however,	  
rapidly	   changing	   as	   antibodies	   and	   other	   reagents	   are	   increasingly	   becoming	  
available	   for	   rats.	  The	  previous	   inability	  of	  embryonic	   stem	  cell	   (ES)	   targeting	   in	  
rats	   has	   also	   led	   to	   development	   of	   other	   efficient	   strategies	   e.g.	   zinc	   finger	  
nuclease	   (ZFN)	   technology	   and	   transposone-­‐mediated	   mutagenesis	   (213,	   214).	  
Moreover,	   the	   first	   rat	   knock-­‐out	   strains	   demonstrate	   that	   recombinant	  
technology	  targeting	  disease	  candidate	  genes	  will	  soon	  be	  standard	  practice	  in	  rat	  
genetic	   studies	   of	   complex	   diseases	   (215).	   Importantly,	   numerous	   inbred	   rat	  
strains	   exist	   in	   various	   laboratories,	   each	   bearing	   its	   own	   susceptibility	   to	   EAE.	  
These	   differences	   in	   EAE	  mostly	   originate	   from	   the	   genetic	   background,	  where	  
some	  strains	  carry	  disease-­‐driving	  variants	  of	  risk	  genes	  and	  others	  carry	  disease-­‐
protective	  variants	  (Figure	  9).	  We	  can	  exploit	  these	  genetic	  differences	  between	  
rodent	  strains	  to	  identify	  the	  disease	  risk	  genes,	  as	  also	  more	  and	  more	  rat	  strains	  
are	  being	  whole-­‐genome	  sequenced	  (216).	  
 
 
































Figure 9. Varying MHC-dependent and non-dependent susceptibilities to EAE in rat strains 
relevant for this thesis. *LEW.1L susceptibility is model-dependent; it is resistant to MOG-EAE 
but susceptible to MBP-EAE. 
 
	  	   25	  
7.	  RESULTS	  AND	  DISCUSSION	  
	  
As	  mentioned	  earlier,	  my	  objective	  has	  been	  to	  identify	  genes	  in	  our	  experimental	  
models	   that	   can	   be	   translated	   as	   risk	   genes	   in	   human	   disease.	   I	   	   also	   wish	   to	  
exploit	   the	   animal	   models	   to	   better	   understand	   the	   pathogenic	   mechanisms	  
conferred	  by	  the	  risk	  genes.	  In	  total,	  my	  four	  papers	  identified	  five	  candidates	  risk	  
genes	   in	   neuroinflammation.	   The	   identification	  of	   these	   genes	   is	   hereby	   shortly	  
summarized:	  	  
7.1.	  POSITIONAL	  CLONING	  
7.1.1.	  Translating	  EAE	  risk	  genes	  to	  MS	  
In	  the	  first	  two	  studies	  of	  this	  thesis	  (Paper	  I	  and	  II),	  we	  successfully	  conducted	  a	  
translational	  three-­‐step	  approach	  to	   identify	  two	  candidate	  genes,	   interleukin	  22	  
receptor	  alpha	  (ll22ra2)	  and	  Vav1.	  We	  first	  defined	  the	  disease-­‐regulating	  regions	  
by	  linkage	  mapping	  in	  the	  rat.	  We	  then	  established	  congenic	  lines	  allowing	  us	  to	  
confirm	   the	  biological	   effect	   and	   refine	   the	  underlying	  pathogenic	  mechanisms,	  
which	   led	   us	   to	   the	   two	   candidate	   genes.	   Finally,	   both	   genes	   (and	   adjacent	  
candidates)	  could	  then	  be	  tested	  as	  MS	  risk	  genes	   in	  several	  cohorts.	   In	  Paper	   I	  
we	  could	  demonstrate	  the	  power	  of	  using	  an	  AIL	  for	  linkage	  studies	  with	  a	  4-­‐fold	  
reduction	   of	   the	   Eae29	   interval,	   compared	   to	   the	   initial	   F2	   intercross	   (217).	   The	  
Vav1	   study	   (Paper	   II)	   specifically	   demonstrated	   a	   near-­‐formal	   proof	   of	   disease	  
regulation	  by	  Vav1	  in	  the	  rat,	  and	  influence	  of	  VAV1	  was	  subsequently	  confirmed	  in	  
six	  MS	  cohorts.	  	  
We	   confirmed	   the	  biological	   importance	  of	  Eae29	   and	  Eae4	  by	   creating	  disease-­‐
protective	   congenic	   lines	   (Figure	   10).	   The	   follow-­‐up	   functional	   studies	   in	   these	  
congenic	  lines	  then	  tested	  for	  differential	  activity	  of	  different	  cell	  types	  between	  
congenics	  and	  parental	  strains.	  In	  a	  stepwise	  manner	  we	  could	  establish	  a	  role	  for	  
Il22ra	  in	  macrophage	  function	  and	  Vav1	  in	  T	  cell	  activity.	  	  















Figure 10. A DA.PVG congenic line carrying resistant Eae29 alleles (A), and DA.BN and 
LEW.BN congenic lines carrying resistant Eae4 alleles (B, C) all reduce disease compared to 
the susceptible parental strains. 
	  
The	  subsequent	  MS	  association	  studies	   indicated	  the	  need	  for	   including	  multiple	  
cohorts.	  The	  observed	  ORs	  were,	  as	  expected,	   rather	   low,	  with	  1.26	  for	   IL22RA2	  
and	   1.18	   for	  VAV1,	   respectively	   (Figure	   11).	   It	  was	   therefore	  necessary	   to	   include	  
several	   thousands	   of	   cases	   and	   controls	   for	   statistical	   significance.	   All	   disease-­‐
associated	   SNPs	   were	   intronic,	   which	   is	   fairly	   common	   for	   association	   studies.	  
Whether	   these	   are	   true	   disease-­‐regulating	   SNPs	   or	   just	   lie	   in	   proximity	   to	  
causative	  SNPs	  remains	  to	  be	  determined.	  Replication	  studies	  by	  performing	  deep	  
sequencing	  of	   the	  genetic	   regions	  surrounding	  the	  associated	  SNPs	  are	   likely	   to	  
more	  accurately	  position	  the	  causative	  polymorphisms.	  	  
	  	  
	  
Figure 11. A polymorphism in IL22RA2 (A) and a haplotype in VAV1 (B-D) both associate 
with MS in combined MS cohorts. 	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7.1.2.	  Epistasis	  in	  EAE	  	  
Papers	   I	   and	   II	   identified	   risk	   genes	   with	   ORs	   in	   the	   range	   of	   1.18	   -­‐	   1.26.	   This	  
reinforces	   the	   observation	   that	   common	   disease	   risk	   genes	   on	   their	   own	   only	  
exert	   small	   effects,	   which	   do	   not	   combine	   to	   completely	   explain	   the	   genetic	  
variance.	   The	   discrepancy	   might	   be	   accounted	   for	   by	   unidentified	   gene-­‐gene	  
interactions,	  which	  are	  difficult	  to	  study	  in	  humans.	  	  
In	   Paper	   III	   we	   used	   an	   eQTL	   mapping	   combined	   with	   pathway	   analysis	   and	  
classical	   QTL	   mapping,	   to	   dissect	   the	   first	   epistatic	   interaction	   on	   a	  
molecular/gene	  level	  in	  EAE.	  We	  identified	  two	  eQTLs	  regulating	  expression	  of	  the	  
NK	  cell	  receptor	  Klrk1,	  and	  its	  ligand	  cluster,	  retinoic	  acid	  early	  transcripts	  (Raet1),	  
respectively	  (218,	  219)(Figure	  12).	  Raet1	  served	  as	  a	  modulator	  of	  Klrk1	  expression	  
that	  ultimately	  regulated	  NK	  cell	  activity	  and	  EAE	  severity.	  	  
The	  eQTLs	  were	  identified	  in	  a	  backcross	  originating	  from	  DA	  and	  PVG	  strains.	  The	  
linkage	  analysis	   revealed	   that	  both	  NK	  cell	   receptor	  and	   ligand	  expression	  were	  
cis-­‐regulated,	   meaning	   that	   the	   eQTLs	   map	   to	   the	   physical	   location	   of	   the	  
regulated	  transcripts.	  Higher	  mRNA-­‐levels	  were	  conferred	  by	  PVG	  alleles	  for	  both	  
transcripts.	  By	  utilizing	  the	  D1cP	  congenic	  line	  that	  carries	  PVG	  alleles	  in	  Raet1	  we	  
could	  confirm	  the	  functional	  importance	  of	  the	  interaction	  on	  NK	  cell	  function	  and	  
abundance.	  Moreover,	  we	   demonstrated	   that	   stimulation	   of	   RAET1	   boosted	  NK	  
cell	  activity,	  which	  could	  also	  reduce	  expansion	  of	  autoreactive	  lymphocytes.	  
This	   study	   illustrates	   how	   experimental	   models	   can	   contribute	   in	   identifying	  
biologically	  relevant	  interactions.	  The	  importance	  of	  the	  Klrk1-­‐Raet1	  interaction	  in	  
MS	  and	  other	  diseases	  remains	  to	  be	  elucidated.	  Perhaps	  of	  greatest	  interest,	  the	  
interaction	   highlights	   an	   interesting	   emerging	   mechanism	   involving	   NK	   cells.	  
These	  mechanisms	  will	  be	  discussed	  in	  more	  detail	  later	  on	  in	  this	  thesis.	  	  
	  	  	  	  	  	  	  	  	  	   	   	  
Figure 12. Epistasis between Raet1 and Klrk1. Expression of the two transcripts correlated in 
the (DAxPVG)xDA backcross. Moreover, genotypes in Raet1 modulated the expression of 
Klrk1 and confirmed the epistasis. RNO1, RNO4 = rat chromosome1 and 4, respectively. 	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7.1.3.	  Shared	  genetic	  risk	  across	  diseases	  
In	   Paper	   IV	  we	   chose	   to	   study	   a	  model	   of	   another	   neuroinflammatory	   disease,	  
GBS.	  We	  hypothesized	  that	  pathogenesis	  between	  EAN	  and	  EAE	  is	  in	  part	  shared.	  
Given	  our	  knowledge	  of	  the	  genetic	  variance	  between	  DA	  and	  PVG	  rat	  strains,	  we	  
established	   a	   (DAxPVG)	   G12	   intercross,	  which	  was	   subjected	   to	   EAN.	  Overlap	   of	  
QTLs	   between	   EAE	   and	   EAN	   would	   indicate	   shared	   pathogenic	   mechanisms	  
across	   diseases.	   The	   study	   identified	   and	   refined	   a	   total	   of	   five	   QTLs,	   all	   being	  
shared	  with	  other	  models	  of	  complex	  inflammatory	  diseases	  (Figure	  13).	  The	  QTL	  
exhibiting	   strongest	   linkage	   to	   clinical	  disease	  was	  Ean6	   on	  RNO12.	  We	  mapped	  
down	   this	   effect	   to	   the	   neutrophil	   cytosolic	   factor	   1	   (Ncf1)	   as	   the	   disease-­‐
regulating	   gene,	   previously	   reported	   to	   regulate	   both	   EAE	   and	   experimental	  
arthritis	   (220,	   221).	  We	  also	  demonstrated	  how	  direct	   stimulation	  of	   the	  NADPH	  
oxidase	  complex	  (NOXC),	  of	  which	  Ncf1	  belongs,	  ameliorated	  EAN.	  We	  therefore	  
suggest	   a	   general	   role	   of	   Ncf1	   and	   the	   oxidative	   burst	   in	   the	   pathogenesis	   of	  
experimental	  autoimmune	  animal	  models.	  
In	   addition	   to	   clinical	   parameters	   we	   used	   splenic	   production	   of	   IFNγ	   as	   a	  
phenotype	   for	   the	   linkage	   study.	   Many	   of	   the	   shared	   QTLs	   linked	   to	   this	  
phenotype	  indicating	  the	  existence	  of	  converging	  immune	  pathways	  that	  involve	  
proinflammatory	   cytokine	   secretion.	   This	   also	  means	   that	   dissection	   of	   disease	  
mechanisms	  in	  EAE	  or	  experimental	  arthritis	  will	  shed	  light	  on	  EAN	  pathogenesis,	  
and	  vice	  versa.	  	  
	  
	  
Figure 13. Shared QTLs between EAE, EA and the refined EAN loci Ean2-6. Blue bars 
denote the regions mapped in the EAN AIL. 
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Logically,	  we	  would	  expect	  to	  find	  both	  shared	  and	  non-­‐shared	  loci.	  In	  this	  study,	  
however,	  all	  EAN	  loci	  overlap	  those	  of	  other	  models.	  	  Although	  the	  same	  genes	  do	  
not	   necessarily	   drive	   all	   shared	   QTLs,	   these	   findings	   strongly	   suggest	   that	   the	  
QTLs	  regulate	  events	  occurring	  in	  the	  immune	  system,	  as	  these	  are	  most	  likely	  to	  
be	   shared	   across	   inflammatory	   diseases.	   This	   would	   fit	   well	   with	   the	   human	  
studies,	  which	  have	  thus	  far	  only	  identified	  immune	  risk	  genes	  for	  MS.	  	  
7.2.	  GENE	  DISCOVERY	  TIMELINE	  
As	  illustrated	  in	  Papers	  I-­‐III	  and	  discussed	  in	  the	  Methods	  section,	  we	  rely	  heavily	  
on	  congenic	  strains	  as	  a	  tool	  to	  fine-­‐map	  disease	  QTLs.	  Depending	  on	  the	  genetic	  
architecture	   of	   the	   QTL	   and	   the	   methodology	   employed,	   the	   timeline	   for	  
identification	  of	  candidate	  genes	  has	  varied	  considerably	  (Figure	  14).	  The	  strength	  
of	   this	   approach	   is	   that	   multiple	   tools	   can	   be	   generated	   simultaneously	   for	   a	  










Figure 14. Timeline for gene discovery in Paper I - IV. Congenization and fine-mapping (blue 
lines) can often be performed simultaneously for multiple loci, e.g. congenization for Paper I 
and III. Moreover, the genes identified in Paper III might not need congenization and may be 
targeted using the emerging strategies in rats.	  
 
Smaller	   congenic	   strains	   require	   more	   generations	   of	   backcross	   breeding.	   The	  
efforts	   to	  obtain	   the	  minimal	   congenic	   strains	   in	  Paper	   II,	   isolating	  a	  <1	  Mb	  QTL	  
including	   less	   than	   ten	   genes,	   largely	   explain	   the	   long	   timeline	   from	   study	  
initiation	  to	  positional	  cloning	  of	  Vav1.	  This	  was	  further	  complicated	  by	  the	  lack	  of	  
prior	  knowledge	  from	  an	  AIL	  or	  eQTLs	  on	  to	  where	  the	  most	  likely	  gene	  location	  
was,	   as	  we	   had	   for	   the	   other	   studies.	   The	  Vav1	   study	   also	   constitutes	   the	   best	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example	  of	  a	  systematic	  stepwise	  dissection	  of	  a	  QTL,	  wherein	  most	  other	  genes	  
within	   the	  original	  QTL	  have	  been	   formally	  excluded.	  We	  were	  also	  hindered	  by	  
the	  physical	   location	  of	  the	  QTL,	  close	  to	  the	  RNO9	  centromere,	  resulting	  in	  low	  
recombination	   frequencies.	   The	   importance	   of	   recombination	   frequencies	   for	  
congenic	  breeding	  is	  illustrated	  in	  Figure	  15,	  which	  compares	  Eae4	  with	  Eae29.	  
Another	   advantage	   both	   Eae29	   and	   Ean6	   offered	   over	   Eae4	   was	   the	   low	   gene	  
density	  within	  the	  QTL	  confidence	  interval.	  This	  allowed	  more	  rapid	  positioning	  of	  
candidate	   genes	   for	   Eae29	   and	   Ean6,	   whereas	   Eae4	   candidate	   genes	   had	   to	   be	  
discerned	   through	   more	   detailed	   and	   tedious	   SNP	   haplotype-­‐phenotype	  
correlations.	  
	  
Figure	   15.	   Recombination	   frequencies	   during	   subcongenization	   for	   the	   Eae29	   and	   Eae4	  
alleles,	  respectively.	  Recombinations	  between	  the	  adjacent	  markers	  D1AO6	  and	  D1Got11	  
(14.9	  –	   17.1	  Mb)	  were	  assessed	   for	  Eae29,	  and	  between	  adjacent	  markers	  D9MJ280	  and	  
D9Rat45	   (1	   –	   3.8	  Mb)	   for	   Eae4.	   Grey	   bars	   represent	   Eae29	   recombinations	   for	   the	   last	  
three	  generations	  of	  congenic	  breeding.	  Red	  bars	  represent	  Eae4	  recombinations	  in	  three	  
representative	  generations	  of	  crossing	  between	  congenic	  lines	  and	  F2	  individuals.	  	  
	  
7.2.1.	  Non-­‐clinical	  phenotypes	  
In	   the	   Vav1	   study	   we	   rapidly	   discovered	   how	   TNF	   production	   of	   splenocytes	  
correlated	   perfectly	   with	   disease	   susceptibility.	   We	   used	   this	   as	   an	   end-­‐point	  
phenotype	   in	   the	   sub-­‐congenization	   of	   the	   initial	   DA.BN-­‐Eae4	   congenic	   strain,	  
thereby	  overriding	   the	  need	   to	   test	   each	   strain	   for	   difference	   in	   clinical	   disease	  
and	  significantly	  reducing	  number	  of	  used	  animals	  and	  time	  necessary	  for	  testing	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minimal	  congenic	  strain,	  R25.	  Without	  this	  approach	  the	  positional	  cloning	  of	  Vav1	  
would	  have	  taken	  considerably	  longer	  time.	  
In	   Paper	   IV	   we	   also	   used	   lymphocyte	   activation	   as	   a	   phentype,	   but	   rather	   for	  
detecting	   QTLs	   in	   the	   linkage	   study.	   IFNγ	   secretion	   by	   activated	   splenocytes	  
reflects	   activity	   of	   mainly	   T	   cells	   and	   we	   therefore	   hypothesized	   that	   IFNγ	  
secretion	   constitutes	   a	   less	   variable	   phenotype	   than	   clinical	   disease	   for	   the	  
identification	  of	  QTLs	  important	  for	  T	  cell	  function.	  We	  identified	  four	  ‘IFNγ’	  QTLs,	  




Considering	  the	  time	  and	  effort	   required	  producing	  congenic	  strains	  and	  testing	  
candidate	  genes	  individually,	   it	   is	   important	  to	   improve	  the	  methodology	  in	  how	  
we	   characterize	   phenotypes.	   Another	   issue	   is	   how	   we	   can	   formally	   exclude	  
candidate	   genes	   within	   a	   QTL	   in	   an	   unbiased	   manner.	   In	   Paper	   III	   we	   could	  
overcome	   some	   of	   these	   obstacles	   by	   using	   genome-­‐wide	   transcript	   arrays	  
combined	   with	   conventional	   linkage	   analysis	   to	   not	   only	   identify	   a	   genetic	  
interaction	  that	  regulated	  expression	  of	   immune	  genes,	  but	  also	  to	   link	  this	  to	  a	  
disease	   mechanism	   involving	   NK	   cells.	   We	   could	   therefore	   perform	   guided	  
experiments	   to	   study	   the	   importance	   of	   the	   NK	   cell	   activity	   and	   lymphocyte	  
expansion.	  By	  using	  genome-­‐wide	  arrays	   in	  our	  congenic	   lines	  we	  will	  be	  able	  to	  
see	  how	  whole	  networks	  are	  affected	  by	  our	  disease	  risk	  genes.	  Given	  the	  density	  
of	  such	  generated	  data,	  the	  problem	  will	   rather	  be	  to	   identify	  the	  most	  disease-­‐
relevant	   time-­‐point	  and	   tissue	   to	   study.	  The	   future	  will	   also	   lie	   in	  more	  efficient	  
gene	   targeting	   that	   can	   be	   performed	   on	   any	   genetic	   background.	   ZFN	  
technology	  and	  lentiviral	  transfection	  are	  examples	  of	  required	  methods,	  but	  also	  
improved	  genome-­‐wide	  pathway	  analysis	  will	  be	  crucial	  in	  efficient	  detection	  and	  
characterization	  of	  risk	  genes.	  With	  genome	  sequencing	  becoming	  more	  feasible	  
we	   will	   have	   access	   to	   multiple	   confirmed	   and	   putative	   targets	   to	   apply	   these	  
technologies	  on.	  	  
7.3.	  PATHOGENIC	  MECHANISMS	  
7.3.1.	  IL22RA2	  and	  innate	  immunity	  	  
The	  association	  of	  IL22RA2	  to	  MS	  illustrates	  the	  importance	  of	  cytokines	  and	  their	  
receptors	  in	  MS.	  Moreover,	  the	  first	  non-­‐HLA	  genes	  identified	  were	  also	  cytokine	  
receptors,	  namely	   IL2RA	   and	   IL7RA	   (33,	  36).	  Cytokine	   receptors	  have	  often	  been	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linked	  with	  T	  cell	  fates;	  for	  example	  signaling	  through	  distinct	  receptors	  skews	  T	  
helper	  cell	  proportions.	  Accordingly,	   IL22RA2	  would	  be	  expected	  to	   involve	  TH17	  
cell-­‐mediated	  effects,	  given	  that	  these	  cells	  are	  major	  producers	  of	  IL22.	  A	  role	  for	  
the	   IL22	   system	   has	   also	   been	   suggested	   in	   other	   studies	   of	   EAE	   and	  MS	   (222,	  
223).	  However,	   in	   our	  D1cP	   congenic,	   T	   cell	   lymphocyte	   activation	   or	   expansion	  
was	  unaffected	  compared	  to	  DA;	   instead	  macrophages	  were	   less	  activated.	  This	  
implies	  a	  role	  for	  Il22RA2	  involving	  innate	  responses.	  	  
	  
As	  Il22RA2	  is	  soluble,	  one	  cannot	  exclude	  the	  possibility	  of	  it	  acting	  as	  a	  ligand	  on	  
an	   as	   yet	   identified	   receptor,	   possibly	   expressed	   on	  macrophages	   or	  microglia.	  
IL22RA2	   may	   alternatively	   function	   as	   a	   carrier	   protein	   for	   its	   ligand	   IL22	   and	  
thereby	   enhance	   long-­‐range	   effects	   and	   stability.	   This	   has	   been	   observed	   for	  
other	  cytokine	  –	  cytokine	  receptor	  systems	  (224-­‐226).	  Assuming	  that	  IL22	  is	  a	  pro-­‐
inflammatory	   cytokine,	   our	   data	   suggest	   an	   IL22-­‐enhancing	   role	   of	   IL22RA2,	   as	  
Il22ra2	  expression	  was	  higher	   in	  the	  susceptible	  DA	  strain.	  The	  mechanism	  could	  
equally	   involve	  microglia,	   considering	   the	   differences	   in	   lesion	   activity	   between	  
D1cP	  and	  DA.	  With	  this	  respect,	  it	  will	  be	  important	  to	  examine	  the	  relative	  impact	  
of	   IL22RA2	   on	   activation	   mechanisms	   versus	   that	   of	   phagocytic	   responses.	  
Inflammatory	   responses	   may	   involve	   cytokine	   and	   receptor	   expression	  
production	   that	   regulate	   antigen	   presentation,	   whereas	   differential	   phagocytic	  
responses	  would	  rather	   imply	  a	  role	   in	  tissue	  destruction	  and	  disease	  chronicity.	  
More	   experiments	   are	   needed	   to	   fully	   characterize	   the	   function	   of	   IL22RA2	   in	  
biology	  and	  disease.	  	  
	  
	  
	  	  	  	  	  	  	  
Figure 16. Il22ra2 expression associates with macrophage activation. Il22ra2 transcripts 
were elevated in the non-B non-T cell compartment. Moreover, activated macrophages from 
the susceptible DA strain secreted higher levels of TNF and other pro-inflammatory molecules 
compared to the more resistant D1cP strain, whereas stimulated LN cells did not.  
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7.3.2.	  VAV1	  and	  adaptive	  immunity	  
VAV1	   is	   an	   intracellular	  multifunctional	   adaptor	  molecule	  with	  a	  well-­‐established	  
role	   in	   T	   cell	   activation	   (227,	   228).	   The	   same	   has	   also	   been	   reported	   for	   other	  
surface	  receptors,	  including	  the	  B-­‐cell	  antigen	  receptor,	  FcεRI,	  FcγRI/II/III,	  growth	  
factor	   receptors,	   integrins,	   cytokine	   receptors	   and	   chemokine	   receptors	   (229).	  
VAV1	   transduces	   these	   receptor	   signals	   to	   various	   pathways	   leading	   to	   cell	  
activation.	  We	  mainly	  studied	  the	  role	  of	  Vav1	   in	  T	  cell	  activation	  and	  expansion.	  
We	   could	   demonstrate	   how	   genetic	   variations	   in	   Vav1	   regulated	   the	   inversely	  
correlated	  production	  of	  pro-­‐inflammatory	  cytokines	  such	  as	  IFNγ	  and	  TNF	  on	  the	  
one	  hand,	  and	  the	  suppressive	  cytokine	  tumor	  growth	  factor	  beta	  (TGF-­‐β)	  on	  the	  
other	   (data	  not	   shown).	  The	  Vav1	   allele	   in	  our	  EAE-­‐susceptible	   strains	  conferred	  
higher	   VAV1	   protein	   levels;	   it	   is	   also	   this	   allele	   that	   mediated	   higher	   pro-­‐
inflammatory	  cytokine	  expression.	  The	  same	  phenotypes	  were	  then	  confirmed	  in	  
human	   blood	   and	   CSF;	   VAV1	   expression	   correlates	   well	   with	   IFNγ	   and	   TNF	  
expression	   and	   higher	   VAV1	   expression	   is	   conferred	   by	   the	   risk	   polymorphism.	  
Moreover,	   in	  rats	  the	  high	  expressing	  allele	  drove	  both	  an	  increased	  lymphocyte	  
expansion	  upon	  re-­‐stimulation	  with	  CNS	  autoantigens,	  and	  also	  lower	  proportions	  
of	  natural	  TREGS	  in	  several	  tissues.	  Collectively,	  our	  findings	  determine	  that	  natural	  
variations	  in	  Vav1	  control	  the	  inherent	  ability	  of	  T	  cells	  to	  respond	  to	  stimuli	  which	  
ultimately	   controls	   their	   ability	   to	   expand	   and	   mediate	   EAE	   (Figure	   17).	  
Apparently,	   the	   relative	   strength	   of	   this	   activation	   signal	   also	   regulates	   TREG	  
proportions.	   Our	   more	   recent	   experiments	   have	   also	   demonstrated	   how	   Vav1	  
variants	   control	   the	   maturity	   of	   thymic	   T	   cells,	   a	   phenomenon	   that	   plausibly	  
controls	  the	  early	  fate	  of	  T	  cells	  and	  promotes	  a	  skewing	  towards	  more	  TREGS.	  We	  
have	   also	   demonstrated	   that	   responses	   to	   B	   cell	   receptor	   stimulation	   are	  
regulated	  by	  Vav1	  alleles.	  In	  the	  context	  of	  EAE,	  Vav1	  appears	  to	  control	  adaptive	  
immune	  responses	  through	  several	  distinct	  mechanisms.	  	  
	  
	  
	  	   34	  
       	  	  
              
Figure 17. Vav1 regulates T cell expansion and TREG proportions. A SNP in exon1 of Vav1 
associates with deregulated TNF production and expansion of T cells, which inversely 
correlates with proportions of TREGS in lymph nodes from immunized rats day 7 p.i. (p=0.02). 
The relative TNF expression of stimulated splenocytes across strains is denoted ranging from 
+ to +++. Splenic TREG proportions were inversely correlated with TNF expression for all 
analyzed strains. 
 
7.3.3.	  NK	  cells	  reduce	  EAE	  	  
The	   epistatic	   interaction	   identified	   in	   Paper	   III	   highlights	   a	   novel	  mechanism	   of	  
regulation	  of	  immune	  response	  by	  which	  NK	  cells	  can	  regulate	  autoimmunity.	  The	  
current	   literature	  suggests	  that	  NK	  cells	  have	  a	  predominantly	  protective	  role	   in	  
MS	   and	   EAE.	   NK	   cells	   have	   been	   described	   in	   experimental	   models	   to	   both	  
mediate	   destruction	   of	   autoreactive	   cells	   and	   directly	   lyse	   dendritic	   cells	   (121,	  
230).	  Our	  data	  also	  demonstrate	  an	  inverse	  correlation	  between	  EAE	  susceptibility	  
and	   splenic	   NK	   cell	   proportions.	   Similarly,	   decreased	   numbers	   of	   NK	   cells	   have	  
been	  detected	  in	  MS	  patients	  (231).	  Therapies	  enriching	  for	  NK	  cell	  numbers	  also	  
ameliorate	   MS	   through	   a	   mechanism	   that	   involves	   inhibition	   of	   autoreactive	   T	  
cells	  (232).	   
Our	  findings	  suggest	  that	  one	  of	  the	  ways	  NK	  cells	  control	  disease	  is	  by	  targeting	  
cells	   expressing	   the	   NK	   cell	   ligands	   retinoic	   acid	   early	   transcripts	   (Raet1).	   We	  
determined	   this	   cluster	   of	   ligands	   and	   its	   cognate	   receptor	   Nkg2d	   to	   be	   more	  
highly	  expressed	  in	  our	  resistant	  strains.	  We	  therefore	  propose	  a	  model	  in	  which	  
overexpressed	   RAET1	   ligands	   lead	   to	   increased	   NK	   cell	   numbers	   during	  
development	   and	   become	   upregulated	   in	   activated	   immune	   cells	   that	   are	  
subsequently	   cleared	   by	   poised	   NK	   cells	   expressing	   the	   activating	   NKG2D	  
receptor	  (encoded	  by	  KLRK1).	  This	  in	  turn	  prevents	  disease	  exacerbation	  through	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a	  mechanism	   involving	   reduced	   expansion	   of	   autoreactive	   lymphocytes	   (Figure	  
18).	  Concordantly,	  we	  demonstrate	  that	  Raet1	  ligands	  are	  produced	  in	  splenocytes	  
and	  lymph	  node	  cells.	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  
 
Figure 18. Proposed model of NK cell-mediated regulation of EAE through the RAET1-
NKG2D system 
7.3.4.	  Shared	  mechanisms	  across	  diseases	  	  
In	  Paper	   IV	  we	   identified	  Ncf1	  as	  a	   risk	  gene	  for	  EAN,	  already	  described	  as	  a	  risk	  
gene	  for	  experimental	  arthritis	  (EA)	  and	  EAE.	  This	  finding	  strengthens	  the	  role	  of	  
T	   cells	   in	   the	  pathogenesis	  of	   EAN.	  A	  high	  Ncf1-­‐activity	   from	  APCs	   is	   thought	   to	  
produce	  oxidative	  reagents	  which	  turn	  reduces	  T	  cell	  activation	  by	  altering	  their	  
membrane	  potential.	  This	  has	  been	  demonstrated	  for	  EA	  and	  EAE,	   two	  diseases	  
with	   a	   clear	  participation	  of	   activated	  T	   cells.	   EAN	   is	   primarily	   a	  model	  of	  AIDP,	  
which	   is	   the	   most	   prevalent	   form	   of	   GBS	   in	   the	   Western	   hemisphere.	   It	   is	  
therefore	  possible	  that	  the	  relative	  importance	  of	  T	  cells	  and	  their	  modulation	  by	  
NOXC-­‐stimulation	   is	   more	   pronounced	   in	   this	   subset	   of	   GBS	   patients.	  
Interestingly,	   the	   protective	   role	   of	   NOXC	   stimulation	   in	   both	   GBS	   and	  MS	   has	  
been	   suggested	   in	   a	   two	   Swedish	   studies	   in	   which	   higher	   NOXC	   activity	   in	  
leukocytes	  correlated	  with	  milder	  disease	  (233,	  234).	  
A	  similar	  disease-­‐overlapping	  role	  is	  evident	  for	  Vav1.	  More	  recent	  data	  in	  our	  lab	  
demonstrates	   that	   Vav1	   regulates	   EA,	   which	   has	   also	   been	   demonstrated	   in	  
association	   studies	   in	   Swedish	  RA	  cohorts	   (data	  not	   included).	   The	  mechanisms	  
involving	  pro-­‐inflammatory	  cytokines,	   lymphocyte	  expansion	  and	  TH	  cell	   subsets	  
are	  also	  likely	  to	  control	  RA.	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8.	  CONCLUSIONS	  AND	  FUTURE	  DIRECTIONS	  
	  
The	  studies	  included	  in	  thesis	  have	  investigated	  distinct	  aspects	  of	  the	  genetic	  and	  
pathogenic	  mechanisms	  regulating	  neuroinflammation.	  I	  have	  herein	  summarized	  
the	   most	   essential	   conclusions	   and	   future	   experiments	   required	   to	   further	  
advance	  our	  understanding.	  
	  
 EAE/EAN	  risk	  genes	  translate	  well	  to	  human	  disease	  	  
Our	  translational	  studies	  (Paper	  I	  and	  II)	  collectively	  demonstrate	  that	  IL22RA2	  and	  
VAV1	  regulate	  both	  EAE	  and	  MS.	  The	  relative	  strength	  of	  the	  rat	  QTLs	  Eae29	  and	  
Eae4	  are	  also	   in	  concordance	  with	  the	  observed	  ORs	  of	  1.18	  and	  1.26	  for	   IL22RA2	  
and	   VAV1,	   respectively.	   This	   supports	   EAE	   as	   a	   good	   model	   of	   MS	   and	   the	  
usefulness	   of	   studying	   genetic	   regulation	   of	   experimental	   models	   in	   order	   to	  
better	  understand	  human	  disease.	  Through	  use	  of	  whole-­‐genome	  sequencing	  and	  
transcript/protein	  profiling	  of	   the	  congenic	   lines	  and	  parental	   strains,	  we	  have	  a	  
chance	   to	   not	   only	   identify	   the	   disease	   risk	   genes,	   but	   also	   to	   locate	   the	   exact	  
variation	   controlling	  disease.	   This	  will	   be	   a	   considerable	   effort	   and	  will	   likely	  be	  
achieved	  through	  large	  genetic	  consortia	  with	  access	  to	  modern	  techniques.	  It	  is	  
also	   important	   that	  human	  and	  experimental	  genetic	   studies	   take	  advantage	  of	  
each	   other’s	   strengths.	   GWAS	   have	   superior	   resolution	   to	   detect	   risk	   SNPs	   and	  
dozens	   of	   such	   SNPs	   are	   being	   discovered	   for	   various	   complex	   disorders	   (163).	  
Upcoming	   large	   GWAS	   from	  MS	   is	   also	   predicted	   to	   unravel	   several	   novel	   risk	  
genes.	   There	   is	   an	   inevitable	   need	   to	   study	   these	   functionally	   in	   patient	   tissue	  
samples,	  but	  also	  in	  experimental	  models	  that	  are	  useful	  since	  conditions	  can	  be	  
controlled	  and	  the	  relevant	  tissue	  is	  readily	  available.	  It	  will	  therefore	  be	  of	  great	  
interest	   to	   functionally	  dissect	  MS	   risk	  genes	   in	   rat	  models	  but	  also	   to	   see	  how	  
risk	  genes	   in	   the	   rat	   relate	   functionally	   to	   the	  ever-­‐growing	   list	  of	   identified	  MS	  
genes.	  
	  
 EAE/EAN	  pathogenic	  mechanisms	  translate	  well	  to	  human	  disease	  	  
Papers	  II,	  III	  and	  IV	  identify	  genes	  important	  for	  several	  mechanisms	  including	  TREG	  
proportions,	   NK	   cell	   activity	   and	   the	   oxidative	   burst	   of	   the	   NOXC.	   We	   also	  
demonstrate	   that	   an	   increased	   activity	   of	   these	   mechanisms	   associates	   with	  
disease	   protection	   in	   our	   models.	   Importantly,	   these	   mechanisms	   have	   similar	  
beneficiary	   roles	   in	   MS	   and	   GBS	   (232-­‐235).	   This	   does	   not	   mean	   that	   they	   are	  
regulated	   by	   the	   same	   risk	   alleles	   as	   in	   the	   rat,	   but	   that	   these	   phenotypes	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constitute	   convergence	   points	   of	   central	   disease	   pathways.	  We	  must	   therefore	  
continue	   to	   experimentally	   dissect	   the	   mechanisms	   regulated	   by	   risk	   alleles.	  
Accordingly,	   risk	   genes	   identified	   in	   human	   cohorts	   should	   be	   studied	  
functionally,	   both	   in	   humans	   and	   models,	   in	   order	   to	   pinpoint	   the	   specific	  
pathways	   they	   regulate.	   The	   ultimate	   goal	   will	   be	   to	   discover	   the	   distinct	  
genotype	   and	   disease	   mechanisms	   important	   for	   each	   patient,	   which	   should	  
greatly	  improve	  therapeutic	  design	  and	  subsequent	  efficacy.	  
	  
 Rodent	   crosses	   and	   congenic	   lines	   are	   good	   tools	   for	   positioning	   of	  
disease	  risk	  genes	  	  
The	   list	   of	   formally	   proven	   risk	   genes	   in	   EAE,	   EAN	  or	   related	  models	   is	   steadily	  
increasing	  (89-­‐92,	  221,	  236,	  237).	  The	  five	  candidate	  genes	   identified	   in	  my	  thesis	  
support	  using	  intercrosses	  and	  congenic	  lines	  as	  tools	  in	  risk	  gene	  positioning.	  In	  
particular,	  the	  DA	  and	  PVG	  strains	  with	  their	  opposing	  EAE	  susceptibilities	  and	  the	  
high	  degree	  of	  natural	  genetic	  variation	  between	   them	  have	  been	  useful	   in	   this	  
regard.	  Studying	  naturally	  existing	  genetic	  variations	  across	  inbred	  strains	  discern	  
a	  more	  realistic	  and	  nuanced	  view	  of	  the	  mechanisms	  that	  risk	  genes	  control.	  This	  
is	  relevant,	  as	  many	  of	  our	  EAE	  risk	  genes	  appear	  to	  have	  multiple	  functions	  that	  
may	   not	   all	   be	   important	   for	   the	   disease.	   In	   such	   a	   scenario,	   looking	   at,	   for	  
example,	   knockout	   strains	   would	   ablate	   all	   these	   mechanisms.	   This	   is	   not	   to	  
reduce	   to	   importance	   of	   knockout	   strains,	   which	   together	  with	   transgenic	   and	  
knock-­‐in	   strains	   can	   offer	   powerful	   complements	   to	   congenic	   lines	   in	   follow-­‐up	  
functional	  studies	  of	  risk	  genes.	  Furthermore,	  the	  controlled	  genetic	  background	  
in	   our	   system,	   which	   enables	   stratification	   of	   genotypes,	   is	   advantageous	   for	  
studying	  epistatic	   interactions.	  We	  can	  thus	  study	  separate	   interactions	  that	  are	  
truly	  important	  from	  those	  which	  are	  merely	  genetically	  regulated.	  Future	  studies	  
must	  aim	  at	  identifying	  the	  level	  of	  redundancy	  and	  relative	  strength	  of	  observed	  
epistatic	  interactions,	  which	  will	  likely	  explain	  part	  of	  the	  missing	  genetic	  variance	  
in	  autoimmune	  disorders.	  	  
	  
 Shared	  genetic	  and	  pathogenic	  components	  across	  diseases	  
As	   discussed	   earlier,	   we	   have	   observed	   many	   examples	   of	   shared	   genetic	   and	  
pathogenic	  mechanisms	  across	  models.	  These	  can	  provide	  therapeutic	  targets	  for	  
the	   specific	   diseases	   they	   regulate.	   TNF-­‐blockage	   in	   RA	   and	   CD	   and	   α-­‐VLA4	  
treatment	  in	  MS	  and	  CD	  are	  good	  examples	  of	  such	  targets	  (50,	  138,	  139,	  238).	  We	  
should	   therefore	  use	  our	   tools	   to	   study	  other	   chronic	   inflammatory	  diseases	  by	  
testing	   our	   congenic	   strains	   in	   other	   inflammatory	  models.	   Conversely,	   disease	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genes	   and	  mechanisms	   identified	   in	   other	   diseases	   should	   be	   evaluated	   in	   EAE	  
and	  MS.	  	  
	  
 The	  identified	  pathogenic	  mechanisms	  involve	  both	  adaptive	  and	  innate	  
immune	  cells	  
Our	   findings	   suggest	   new	   perspectives	   for	   understanding	   the	   roles	   of	   several	  
immune	   cells	   in	   the	   pathogenesis	   of	   EAE	   and	  MS.	   Among	   innate	   cells,	   NK	   cells	  
regulate	   disease	   through	   targeting	   immune	   cells	   expressing	   RAET1	   ligands,	   and	  
macrophages	  can	  both	  drive	  disease	  through	  the	  activity	  of	  the	  soluble	  receptor	  
IL22RA2,	  and	  ameliorate	  disease	  through	  oxidative	  burst	  in	  the	  interaction	  with	  T	  
cells.	  Adaptive	   immune	  cells,	  B	  and	  T	  cells,	  drive	  disease	  through	  VAV1-­‐mediated	  
activation	  and	  expansion;	  the	  strength	  of	  this	  signal	  also	  appears	  to	  also	   impact	  





To	  summarize,	   in	  our	  studies	  we	  have	  used	  the	  EAE	  model	  to	   identify	  risk	  genes	  
that	   modulate	   disease	   susceptibility	   and	   severity	   and	   also	   to	   determine	   which	  
conserved	   immune	   mechanisms	   they	   regulate.	   These	   mechanisms	   are	   in	   turn	  
likely	  to	  translate	  to	  humans	  with	  the	  goal	  of	  improving	  disease	  prognosis,	  better	  
understanding	  of	  the	  pathogenesis	  and	  to	  tailor	  therapies.	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  Gustavo,	  mi	  argentino	  preferido!	  The	  day	  you	  will	  also	   learn	  
Tigrinya	  will	  bring	  a	  	   to	  my	   face,	  Aurélie,	   for	  nice	   talks	  and	  good	   luck	   in	   three	  
weeks!,	  Maria	  and	  Mikkis,	   for	  your	  great	  sense	  of	  humor,	  Marcus,	   for	  being	  the	  
Rheuma	  brewer,	  Emelie,	  for	  the	  “what-­‐after”	  talks,	  Lasse,	  for	  all	  the	  IT-­‐help,	  Eva	  
J,	   Eva	  L,	   Lena,	  Lotta,	  Gull-­‐Britt,	  Marianne	   and	  Åse,	  you	  are	  all	   always	  so	  helpful	  
and	  make	  the	  floor	  less	  chaotic,	  Peter,	  for	  shared	  times	  with	  “Frustaren”,	  Jenny,	  
Ferdinand,	  Maria,	  Leonid,	  Helena,	  Marie	  W,	  Lars	  K,	  Marina,	  Hanna,	  Hiba,	  Vijole,	  
Vilja,	  Vivi,	   Jayesh,	  Shankar,	   Julia,	  Rudiger	  and	   Ingela,	   for	  many	  nice	  chats	   in	  the	  
corridor.	  
Floor	   4	   in	   general,	   for	   great	   atmosphere.	   They	   call	   us	   “Floor	   Bohemia”	   for	   a	  
reason,	  but	  despite	  the	  chaos	  so	  much	  people	  on	  so	  little	  space	  must	  bring,	  you	  
all	  create	  a	  very	  nice	  environment	  to	  work	  in.	  Not	  to	  mention	  the	  cakes…	  
The	  floor	  00	  connection:	  Lollo,	  Anna,	  Malin,	  Karin,	  Felipe,	  Selim,	  Ryan,	  Ida,	  Santi.	  I	  
have	  had	  great	  fun	  hanging	  out	  with	  you	  all.	  Past	  and	  present	  members	  of	  the	  MS	  
group,	  especially	  Boel,	  Jenny,	  Rasmus,	  Iza,	  Kerstin	  and	  Malin,	  thank	  you	  for	  many	  
nice	  chats	  on	  MS	  genetics	  and	  for	  making	  floor	  00	  even	  nicer.	  
A	  mis	  amigos	  catalanes:	  Esther,	  Gloria,	  Toni,	  Regina,	  Elia,	  Carme,	  Alberto,	   Lydia,	  
Polinka	   and	  Martina	   (well	   you	   are	   almost	   Spanish).	   I	   will	   never	   forget	   “Tu	   lo	  
sabe”…	  haha.	  You	  all	  made	  my	  time	  in	  Barcelona	  amazing	  and	  took	  care	  of	  me	  as	  
if	  I	  was	  family.	  No	  other	  people	  could	  have	  made	  such	  a	  large	  project	  so	  pleasant.	  
All	   other	   co-­‐authors	   for	   great	   collaborations,	   especially	   Alex	   H.	   My	   projects	  
would	  not	  have	  been	  what	  they	  are	  without	  your	  help.	  	  
AKM	  staff,	  Katerina	   and	   the	   IT-­‐staff,	   for	  making	  our	  work	  easier.	  Asmelash,	   for	  
being	  my	  habesh	  connection	  on	  the	  floor	  and	  the	  many	  great	  conversations.	  All	  
wonderful	   people	   at	   “Glada	   restaurangen,”	   for	   giving	   me	   extra	   on	   the	   plate	  
without	  me	  having	  to	  ask	  for	  it	  .	  The	  CNS	  administration,	  especially	  Gullan,	  Anki,	  
Rebecca	  and	  Eva,	  for	  always	  helping	  out	  when	  I	  am	  late	  which	  is	  always	  the	  case.	  
The	   sponsors	   of	   my	   work:	   Torsten	   and	   Ragnar	   Soderberg	   Foundation,	  Montel	  
Williams	   Foundation,	   The	   Swedish	   Society	   for	   Neurologically	   Disabled	   and	  
EURATools.	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Davor,	  Petra,	  Maja	  H,	  Robert,	  Fredrik	  W,	  Daniel,	  Roza	  and	  Ola	  and	  many	  more	  for	  
so	  much	  great	  times	  and	  supportive	  talks	  during	  all	  these	  years	  at	  KI.	  I	  am	  lucky	  to	  
know	   you	   all.	   Fredrik	  W,	  Aman	   and	  Nimrod,	   for	   great	   science	   discussions	   that	  
challenged	  my	  way	  of	  thinking.	  
My	  friends	  outside	  of	  CMM,	  the	  list	  is	  too	  long	  to	  include	  but	  you	  know	  who	  you	  
are.	  I	  know	  I	  have	  not	  seen	  most	  of	  you	  lately	  but	  I	  look	  forward	  to	  meeting	  you	  
all	  soon.	  
My	  wonderful	  parents	  Daniel	  and	  Fekar,	  for	  always	  supporting	  and	  believing	  in	  me	  
and	  Admass,	  for	  always	  listening	  and	  challenging	  my	  thoughts	  ,	  I	  love	  you	  all	  so	  
much.	  The	  rest	  of	  my	  dear	  family	  here	  in	  Sweden,	  in	  Eritrea	  and	  elsewhere,	  even	  
though	  we	  are	  not	  always	  near	  in	  face	  we	  are	  always	  near	  at	  heart.	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